Healthcare & Life Sciences — April 2, 2026

FY 2027 Skilled Nursing Facility Prospective Payment System Proposed Rule

CMS issued a proposed rule (CMS-1843-P) updating Medicare payment policies and rates for skilled nursing facilities under the SNF Prospective Payment System for FY 2027. The proposed payment update is 2.4%, based on a 3.2% market basket update offset by a 0.8% productivity adjustment. CMS also proposes changes to the SNF Quality Reporting Program and Value-Based Purchasing Program.

Medicare Inpatient Psychiatric Facility Payment System Updates for FY 2027

CMS issued a proposed rule to update Medicare payment policies for Inpatient Psychiatric Facilities (IPF) for FY 2027, proposing a 2.3% payment rate update representing a $50 million increase in total payments. The rule includes proposals to reform outlier payment policy, remove two measures from the IPF Quality Reporting Program, and implement a standardized IPF patient assessment instrument.

FY 2027 Inpatient Rehabilitation Facility Prospective Payment System Proposed Rule

CMS issued a proposed rule updating Medicare payment policies for Inpatient Rehabilitation Facilities for FY 2027, proposing a 2.4% payment rate increase based on a 3.2% market basket update less a 0.8% productivity adjustment. The rule includes an estimated $355 million increase in IRF payments, updates to outlier thresholds and case-mix weights, and proposes clarifying that all therapies must be initiated within 36 hours of IRF admission.

FY 2027 Hospice Wage Index Payment Rate Update and Quality Reporting Program Proposed Rule

CMS issued proposed rule CMS-1851-P to update Medicare hospice payments for FY 2027, proposing a 2.4% payment rate increase ($785M estimated impact). The rule includes new Service and Spending Variation Index (SSVI) for oversight, mandatory hospice election addendum requirements, and changes to physician designee discharge authority.

Medicare Advantage and Part D Contract Year 2027 Final Rule

CMS issued a final rule updating Medicare Advantage and Part D programs for Contract Year 2027. The rule modifies the Star Ratings system by removing 11 administrative measures and adding a depression screening measure, while codifying Inflation Reduction Act provisions including elimination of the coverage gap phase and reduced annual out-of-pocket thresholds. The rule impacts Medicare Advantage organizations, Part D sponsors, and approximately 66 million Medicare beneficiaries.

Hospice Scoring System for Fraud Detection and Transparency

CMS announced a proposed rule (FY 2027 Hospice Wage Index and Payment Rate Update) introducing a new Hospice Service and Spending Variation Index (SSVI) to publicly score hospice providers based on indicators of inappropriate utilization, quality of care, and compliance concerns. The scoring system aims to combat fraud in the Medicare hospice program, with enhanced oversight already resulting in over 200 enrollment revocations in Arizona, California, Nevada, and Texas, now expanding to additional states.

IRF Payment Rates and Quality Reporting Updates for FY2027

CMS published a proposed rule to update Inpatient Rehabilitation Facility (IRF) payment rates and quality reporting requirements for Fiscal Year 2027. The rule affects Medicare-certified IRFs and proposes changes to payment methodology and quality measure reporting under the IRF Quality Reporting Program.

SNF Prospective Payment System FY2027 Quality Reporting Updates

CMS published a proposed rule updating the Skilled Nursing Facility Prospective Payment System quality reporting requirements for FY2027. The rule proposes changes to standardized patient assessment data reporting under the Minimum Data Set and modifies quality measures for the SNF Quality Reporting Program. Skilled nursing facilities participating in Medicare would be subject to these updated reporting requirements and potential payment adjustments tied to quality performance.

Hospice Wage Index FY 2027 Payment Update Proposal

CMS has published a proposed rule to update the hospice wage index and payment rates for Fiscal Year 2027. The proposal affects Medicare-certified hospice providers and includes changes to routine home care rates, continuous home care rates, and other service payment categories. Comments are being solicited on the payment methodology updates and wage index adjustments.

FY 2027 IPF Payment Rate Update

CMS published a proposed rule updating Inpatient Psychiatric Facility (IPF) payment rates for Fiscal Year 2027. The notice affects Medicare-participating IPFs and includes potential changes to payment amounts, wage indices, and facility-level adjustments. Public comments are being accepted through the specified deadline.

Anthem Policy Penalizes In-Network Facilities for Out-of-Network Provider Use

Anthem (Elevance Health) implemented a Facility Administrative Policy effective January 1, 2026, imposing a 10% penalty on in-network facilities that use out-of-network providers for Anthem's commercial plan members. The policy applies to Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, Ohio, and Wisconsin, with California expansion planned for June 1, 2026. Facilities may face network termination for continued violations.

340B Litigation Roundup - Contract Pharmacy Disputes

McDermott Will & Emery published its weekly 340B litigation roundup covering March 24-30, 2026, summarizing developments across more than 50 pending cases involving the 340B drug pricing program. Drug manufacturers filed new suits challenging state contract pharmacy laws in Washington and pursued appeals in Tennessee cases, while four Utah cases advanced with plaintiffs responding to show cause orders.

LEAD Model Request for Applications for Accountable Care Organizations

The Centers for Medicare & Medicaid Services (CMS) Innovation Center released the Request for Applications (RFA) for the Long-term Enhanced Accountable Care Organization Design (LEAD) Model, a 10-year voluntary demonstration program beginning January 1, 2027. The LEAD Model succeeds the ACO REACH model and introduces new features including CMS Administered Risk Arrangements (CARA) for episode-based risk arrangements with specialists. Applications must be submitted by May 17, 2026.

Automatic Medicare Advantage Enrollment with Opt-Out Option

CMS is reportedly considering feasibility models for automatic Medicare Advantage (MA) enrollment with opt-out provisions for new Medicare beneficiaries, according to remarks by Chris Klomp, chief counselor at HHS and director of the Center for Medicare at CMS. The proposal would allow individuals to opt for traditional Medicare or accountable care organizations instead. This represents early-stage policy exploration and is not yet a formal regulatory proposal.

Drug Testing Guidance for Oklahoma Employers Under Medical Marijuana Law

McAfee & Taft published practical guidance on Oklahoma's medical marijuana employment law, explaining how employers may designate safety-sensitive positions and take adverse action based on positive marijuana tests under the Unity Bill (Okla. Stat. tit. 63, § 427.8(H)(2)(c)). The guidance analyzes the exception to the general anti-discrimination rule for positions involving safety-sensitive duties, including driving, equipment operation, and direct patient care.

FDA Final Guidance on Voluntary Patient Preference Information for Medical Devices

FDA published updated final guidance on incorporating voluntary patient preference information (PPI) in medical device decision making, replacing the 2016 PPI guidance. The guidance fulfills MDUFA V commitments and provides recommendations on study design, submission practices, and inclusion of PPI in device labeling and decision summaries. PPI remains voluntary but FDA may consider it when meeting applicable requirements.

CIPO Updated Patent Guidelines for Medical Diagnostics and CII

CIPO issued practice notice updating guidelines on patentable subject matter for computer-implemented inventions and medical diagnostic methods, superseding PN2020-04 and existing MOPOP provisions. The guidance emphasizes a physicality requirement for patentability and clarifies how claim elements characterized as common general knowledge will be evaluated during purposive construction.

New ALF Specialty License for Memory Care Services

Florida Senate Bill CS/CS/SB 1404 proposes a new Assisted Living Facility (ALF) specialty license designation for memory care services. The bill would require ALFs serving memory care residents or advertising such services to obtain the designation from the Florida Agency for Health Care Administration (AHCA). AHCA must establish minimum standards including staff training requirements, safety protocols, and advertising restrictions by July 1, 2027.

FCA Claims Related to 340B Drug Pricing Program May Proceed

The Ninth Circuit reversed dismissal of a qui tam action in United States ex rel. Adventist Health System of West v. AbbVie Inc., holding that FCA claims tied to alleged 340B ceiling-price noncompliance may proceed at the pleading stage. The court rejected arguments that the absence of a private right of action under 340B bars FCA suits, finding FCA claims are 'free-standing and independent' and can proceed where relator alleges government overpayment harm.

Measles Exposure Locations Confirmed in Oregon

Oregon Health Authority and Clackamas and Multnomah County public health officials confirmed two new measles exposure locations: Lark Café in West Linn (March 27, 12-3 p.m.) and Pho.Com restaurant in Gresham (March 25, 4-6:30 p.m.). Individuals present at these locations during the specified times should contact their healthcare provider to assess measles immunity status.

Measles Exposure Location Confirmed at Providence Portland Medical Center

Oregon Health Authority and Multnomah County announced a measles exposure location at Providence Portland Medical Center emergency department waiting room (4805 NE Glisan St., Portland) on March 30, 2026, between 7:57 p.m. and 10:08 p.m. Individuals present during this timeframe should contact their healthcare provider immediately to assess measles immunity status. Public health officials advise calling ahead before seeking in-person care to prevent potential exposure in waiting rooms.

Death with Dignity Act Prescription Statistics 2025

The Oregon Health Authority released its 28th annual report on the Death with Dignity Act, showing prescriptions for lethal medications increased approximately 5% from 609 to 637 in 2025. Deaths from DWDA drug ingestion totaled 400, a 5% decrease from 421 in 2024, though officials expect this number may rise as death certificates are finalized.

Maryland adds RAD drug data to overdose tracking

The Maryland Department of Health announced the addition of Rapid Analysis of Drugs (RAD) program data to the Maryland Overdose Data Dashboard. The RAD program, launched in 2021, has tested over 6,000 samples from 15 jurisdictions and is used to identify emerging substances like xylazine and medetomidine in the drug supply. The dashboard update provides treatment providers and public health officials with real-time data on substances circulating in Maryland communities.

Medicare Advantage Compliance Audit - Priority Health Diagnosis Codes

HHS OIG completed a compliance audit of Priority Health (Contract H2320) examining diagnosis codes submitted for Medicare Advantage risk adjustment. The audit found that 252 of 300 sampled enrollee-years had medical records that did not support the submitted diagnosis codes, resulting in $828,010 in net overpayments for the sample. Extrapolating to the full population, OIG estimated Priority Health received at least $4.4 million in net overpayments for 2018 and 2019. Priority disagreed with the findings and recommendations.

Lead Recall Dino Nuggets Walmart 29-oz

The Rhode Island Department of Health announced a lead contamination recall for Dino nuggets sold at Walmart in 29-oz bags. Consumers who purchased the affected product should not consume it and should dispose of the product immediately. This is a standard public health food safety notification.

Cair LGL 1mm Lateral Extension Set Recall

ANSM has mandated a recall of specific lots of Cair LGL 1mm lateral extension sets (Prolongateur Cair LGL 1mm latéral) at the agency's request. The manufacturer Cair LGL has implemented the lot withdrawal, and affected users have received notification letters dated 02/04/2026. The recall is registered under ANSM reference number R2607673.

Cook Medical Product Recall - Multiple Medical Device References

ANSM issued a safety recall notice (Ref. R2607073) for multiple Cook Medical medical devices distributed in France. Affected products include Blue Rhino G2 tracheostomy kits (the only products distributed in France), central venous catheters, pleural drainage devices, NCompass biliary stone extractors, and CTO-12 micro wire guides. Users who received the affected products should have received direct notification from Cook Medical.

Getinge Steam Sterilizer Safety Recall for Pre-September 2019 Devices

ANSM has recorded a safety action (R2609375) initiated by Getinge Sterilization AB regarding steam sterilizers manufactured before September 4, 2019. Healthcare facilities using affected devices have received a manufacturer letter with safety instructions. This recall targets hospital pharmacies, health establishments, and city care structures in France.

Maincare IC Prescription Module Safety Notice

ANSM issued a safety notice (n° R2609195) informing healthcare services that Maincare Solutions has implemented a security action on its IC prescription module software. Users of the affected software have received direct correspondence from the manufacturer regarding this action.

Inogen Rove 6 oxygen concentrator safety notice

ANSM has issued safety notice R2608138 informing three French home health providers about a field safety corrective action by manufacturer Inogen Inc. regarding the Inogen Rove 6 portable oxygen concentrator. The action was conducted directly by Inogen Inc., with ANSM acting as the notification authority. Providers should consult the attached manufacturer correspondence for specific safety instructions.

Ophthalmic System with Patient-Customized Alignment Mechanisms

USPTO published patent application US20260090717A1 by Carl Zeiss Meditec covering an ophthalmic system (OCT or fundus imager) with patient-customized alignment mechanisms. The system enables single-operator fine alignment using custom mechanical guides and rough pre-alignment based on patient-specific parameters. Application 19341552 was filed September 26, 2025.

Visual Acuity Testing with Astigmatism

USPTO published patent application US20260090713A1 for a method and device determining visual acuity characteristics of subjects with astigmatic visual defects. The invention uses preferential direction testing aligned with cylinder axis correction, adapted visual signs with directional features, and optical power application to measure acuity in specific orientations. Inventors are Adam Muschielok and Stephan Trumm.

Fundus Imaging Apparatus with OCT

USPTO published patent application US20260090714A1 for a fundus imaging apparatus combining standard color imaging with optical coherence tomography (OCT) technology. The application claims a compact design with a control unit positioned above the optical systems and an exhaust port for thermal management. Inventors include Yusuke Oogi, Rui Fukuoka, and Daisuke Baba.

Retinal Image Processing Method Using Multispectral Imaging for ML Training

USPTO published patent application US20260090719A1 for a computer-implemented method of processing retinal images using multispectral imaging and machine learning. The invention assesses image quality by determining artifact extent across different wavelengths and computing a quality index to determine suitability for training machine learning algorithms. Inventors include Claudia Chevrefils, Gabriel Dignard, Wei You, and Jean-Philippe Sylestre.

Scanning laser ophthalmoscope fluorescent imaging patent application

USPTO published patent application US20260090718A1 for a scanning laser ophthalmoscope capable of obtaining visible light images and fluorescent images of the ocular fundus. The application claims a system including visible and infrared light sources, a scanner, beam splitter, and multi-channel light detection unit with red, green, and blue/fluorescence detection capabilities. Inventors: Sun Hyung JO and Woo Kyung BEAK.

Eye Spectropolarimetry for Neurodegenerative Disease Markers

USPTO published RETISPEC Inc.'s patent application US20260090709A1 for systems and methods evaluating eye spectropolarimetric data to identify markers of neurodegenerative diseases affecting the central nervous system. The filing (application 19214892) covers imaging analysis using spatial, spectral, and polarimetric data to classify patients into disease status categories. The application was filed May 21, 2025.

Double Tagged Serratia Marcescens Nuclease Patent Application

USPTO published patent application US20260092265A1 for a double-tagged Serratia Marcescens Nuclease (SMN) engineered with a C-terminal Chitin Binding Domain (CBD-tag) and a 6-mer poly-histidine tag connected by a Gly-Ser linker. Inventors: Dapeng Sun, Aine Quimby, Zhenyu Zhu. Application No. 19324955 was filed September 10, 2025.

Fusion protein complexes for epigenetic regulation, cancer treatment

USPTO published patent application US20260092267A1 by inventors Seung Ja Oh and Na Ly Tran for fusion protein complexes including transcription enhancers and dCas9 proteins for epigenetic regulation. The application covers complexes with guide RNAs (gRNAs) for inducing apoptosis of colorectal cancer cells and compensating for rhodopsin deficiency to treat ocular diseases.

CRISPR Enzymes and Systems

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

Modified GlcNAc-1-Phosphotransferase sequences, patent application

USPTO published patent application US20260092263A1 for modified, truncated GlcNAc-1-Phosphotransferase (PTase) amino acid sequences that retain phosphotransferase activity. The application, filed August 4, 2025 (Application No. 19289364), covers truncated PTase forms lacking or with modified linkers and/or lacking the C-terminal transmembrane and cytosolic domain, demonstrating retained ability to phosphorylate lysosomal or non-lysosomal target proteins.

Bacteriophage structural proteins via cell-free expression system

The USPTO published patent application US20260092261A1 for multi-peptide structures comprising heterologous functional sites derived from bacteriophage structural proteins produced via cell-free expression. The application, filed by Elisabeth Falgenhauer and co-inventors Friedrich Simmel, Kilian Vogele, and Sophie von Schönberg, covers compositions and methods for universal anti-microbial applications in medicine, chemistry, biotechnology, agriculture, and food industry.

Glucosyltransferase Mutant Converting Rebaudioside D to Rebaudioside M

USPTO published patent application US20260092262A1 for Shandong Benyue Biological Technology Co., Ltd covering a glucosyltransferase mutant enzyme that catalyzes conversion of Rebaudioside D (RD) to Rebaudioside M (RM). The mutant contains specific amino acid substitutions at positions 84, 88, 126, 196, and 379 and exhibits significantly higher enzyme activity than wild-type variants. The application was filed September 26, 2025.

Cell Adhesion System for Interspecies Chimeras

USPTO published patent application US20260092259A1 by inventors Jun Wu, Emily B. Ballard, and Jia Huang for a cell adhesion system enabling formation of interspecies chimeras through engineered cells expressing antigen-binding proteins or antigens with cell membrane signaling peptides. The invention facilitates generation of organs, organoids, or tissue masses from human and non-human chimeric animals for potential transplant applications.

Low-Temperature Preservation Cabinet with Temperature Isolation for Biological Samples

USPTO published patent application US20260092260A1 by Genepoint Technologies (Shanghai) Co., Ltd. for a low-temperature preservation cabinet designed for biological samples, featuring a storage region, equipment region, and temperature isolation zone between them. The filing date was December 8, 2025, with application number 19412761.

Adaptive AI system identifies mental illness behaviors, modifies treatment plans

USPTO published patent application US20260094689A1 for an adaptive AI system that identifies behaviors associated with mental illness and modifies treatment plans. The system predicts typical and aberrant physiological reactions to psychiatric counseling using demographic and biometric data. Filed by Federal Leadership Institute, Inc.

Neural Network Training Corpus for Radiation Treatment Platform Control

The USPTO published patent application US20260094688A1 on April 2, 2026, covering neural network training methodology using physical settings data from a specific radiation treatment platform. Inventors Shahab Basiri and Esa Kuusela describe a training corpus that excludes data from other platforms, with retraining triggered by time, usage count, or maintenance events. The trained neural network maps optimized treatment plan control points to corresponding machine control points. No compliance deadlines or penalties apply.

Error Correction with Embedded Parity for Digital Images

USPTO published Patent Application US20260094691A1 titled 'Error Correction with Embedded Parity' by inventor Sanjay M. Joshi. The application discloses methods for protecting digital image files from loss through encoding, distributed check symbol embedding, and error recovery using error correction blocks. The technology applies to digital image transmission and storage systems.

Child Evaluation System and Method of Use

USPTO published patent application US20260094690A1 for a child developmental delay diagnosis system by inventors Susan O. Gunduz and Stephanie Anne Denton. The system provides methods for early diagnosis and treatment of developmental delays in children, covering motor skills, language, phonological processing, and social emotional regulation. The patent application was filed on September 30, 2025, under application number 19344768.

Medical Information Processing Apparatus and Method for Time-Series Organ Images

Canon Medical Systems Corporation filed USPTO Patent Application US20260094692A1 for a medical information processing apparatus and method. The invention processes time-series images of target organs to identify organ regions and attached device regions, then calculates an index based on changes in the relative position of the device with respect to the organ in a specified attention direction. The patent was published April 2, 2026 with inventors Keitaro Kawashima and Gakuto Aoyama.

Emboli Detection Methods Using Ultrasound Signals

MIT has filed USPTO Patent Application US20260094694A1 for emboli detection methods using ultrasound signals to identify mechanisms of brain injury in susceptible adults and children. The technology processes ultrasound data to identify candidate embolic regions, filter them to identify actual embolic regions, and output embolic information for clinical use.

Multi-Modal Multi-Task Foundational Models for Medical Image Manipulation

The USPTO published patent application US20260094693A1 on April 2, 2026, disclosing a multi-modal AI system developed by inventors Alexandru Constantin Serban, Mehmet Akif Gulsun, Puneet Sharma, and Dorin Comaniciu for medical image manipulation and information retrieval. The system receives text-based instructions, encodes them using machine learning text encoders, and determines and performs instructions through medical applications to generate responses. The publication affects medical device makers, healthcare technology providers, and AI developers working on clinical applications.

Heterocyclic JAK Inhibitors and Canine Atopic Dermatitis Treatment

The USPTO published patent application US20260092070A1 filed by Andrew Antony Calabrese and David T. Stanton for heterocyclic compounds that inhibit Janus Kinase 1 (JAK-1) enzymes. The compounds are designed for treating inflammatory disorders in non-human mammals, specifically canine atopic dermatitis. The application was filed December 2, 2025, under Application No. 19405620.

Annelated Pyridines as Steroidogenesis Inhibitors

USPTO published patent application US20260092074A1 by Hoffmann-La Roche covering annelated pyridine compounds as steroid synthetase inhibitors for pharmaceutical use. The application, filed September 25, 2023, discloses small-molecule heterocyclic compounds (C07D class) with applications in steroid hormone regulation. Inventors include Qingzhong Hu, Lina Yin, and Haiyan Li.

Novel Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092073A1 by Hoffmann-La Roche Inc. for novel heterocyclic compounds with general formula I, including compositions and methods of use. The application (Filing Date: 2025-10-15) covers compounds where R1, R2, R9, A1, Rx and Ry define specific substituents. Inventors include David BON, Lea Aurelie BOUCHE, Wolfgang GUBA, and others. CPC Classification: C07D 498/04.

Substituted Indazoles IRAK4 Inhibitor Patent Application

The USPTO published patent application US20260092069A1 by inventors Terstiege, Schiesser, Xue, Chang, and Berggren for substituted indazoles as IRAK4 inhibitors with potential therapeutic utility. The application (No. 19343252) was filed September 29, 2025 and published April 2, 2026. IRAK4 inhibitors target inflammatory and autoimmune pathways.

Aldose Reductase Inhibitors for Skin Aging and Cardiovascular Disorders

USPTO published patent application US20260092072A1 by inventor Andrew WASMUTH for aldose reductase inhibitor compounds. The application covers novel pharmaceutical compositions for treating skin aging, cardiovascular disorders, renal disorders, cancer, diabetes complications, and related conditions. The filing (Application No. 19414626) was submitted December 10, 2025, and classified under CPC codes C07D 495/04 and C07H 15/26.

SMARCA2/4 Degrader Compounds and Compositions Patent

USPTO published patent application US20260092071A1 for compounds of Formula II as SMARCA2 or SMARCA4 degraders, including their pharmaceutical compositions and uses. The application (No. 19112750) was filed on September 22, 2023, with 14 inventors including Shaomeng Wang and colleagues. This is a publication of a patent application in the field of heterocyclic compounds for potential therapeutic use.

Patent for micheliolide compositions to increase muscle mass

USPTO published patent application US20260091019A1 by Korea Institute of Science and Technology for a pharmaceutical composition containing micheliolide as an active ingredient for increasing muscle mass, improving muscle function, or preventing or treating muscular disease. The application (No. 19302634) was filed August 18, 2025 and published April 2, 2026, listing 12 inventors including Myungsuk Kim and Choong-Gu Lee.

Treatments for Inflammation - Connexin Hemichannel Modulators

USPTO published patent application US20260091017A1 by inventors Shome, Mugisho, and Rupenthal for inflammation treatment compounds and methods using connexin hemichannel modulators, inflammasome modulators, and pannexin channel modulators. The application covers compositions for treating ocular and dermatological diseases characterized by inflammasome-mediated inflammation through systemic and topical administration. Application No. 19342361 filed September 26, 2025.

Panobinostat Combination Therapy for Cholangiocarcinoma Treatment

The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.

Treatment of Acute Cannabinoid Overdose

USPTO published patent application US20260091020A1 for methods of treating acute cannabinoid intoxication and metrics for evaluating cannabis intoxication. Inventors are Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, and Kenneth C. CUNDY, with application filing date of September 25, 2023.

Chrysin Pinocembrin CAPE Composition for Neuroinflammation Prevention

The USPTO published patent application US20260091016A1 claiming a composition comprising chrysin, pinocembrin, and CAPE (caffeic acid phenethyl ester) for preventing or treating neuroinflammation and associated neuropsychiatric and neurological diseases. Application No. 18904297 was filed October 2, 2024. The composition is classified under CPC codes A61K 31/352, A61K 31/216, A61K 35/644, and A61P 25/28.

Neurotoxin Compositions for Treating Gastroparesis

USPTO published patent application US20260091094A1 disclosing neurotoxin compositions and methods for treating gastroparesis. Inventors Gregory F. Brooks and Eric Carter filed the application on December 9, 2025, under application number 19413766. The publication constitutes prior art as of April 2, 2026.

Netrin-1 peptide amphiphiles treat central nervous system injury

USPTO published patent application US20260092252A1 for Netrin-1 mimetic peptide amphiphiles for treating central nervous system injury. The application covers peptide compositions and methods of use. Inventors include Samuel Isaac Stupp, Cara Stephanie Smith, and Zaida Alvarez Pinto.

Heparan-N-sulfatase purification via multi-mode chromatography

The USPTO published patent application US20260092264A1 on April 2, 2026, disclosing a novel method for purifying heparan-N-sulfatase using multi-mode chromatography combined with caprylate precipitation. Invented by six researchers, the method removes host cell proteins and improves purity and stability of the enzyme for potential pharmaceutical applications.

Adeno-Associated Virus Producer Cell Lines Patent Application

The USPTO published patent application US20260092284A1 for Adeno-Associated Virus (AAV) producer cell lines and methods of producing AAVs. The application, filed August 15, 2025, covers nucleic acids encoding helper genes and AAV genes under inducible promoter control, as well as mammalian cell lines for AAV production. Inventors include Bingnan Gu, Gang Li, and Caitlin Tripp.

ActRIIB ectodomain variants treating metabolic disorders and fibrosis

USPTO published patent application US20260092096A1 for Activin receptor type IIB (ActRIIB) ectodomain variants fused to Fc domain for treating metabolic disorders, diabetes, obesity, fibrosis, and muscle atrophy. The application (No. 19206991) was filed May 13, 2025, by inventors Maureen D. O'Connor-McCourt et al.

LBA Laboratoires De Botanique Trademark Application

USPTO published trademark application TM79424086 for LBA LABORATOIRES DE BOTANIQUE AVANCÉE BAULIEU in International Class 005 covering cosmetics, beauty products, spa services, and retail store operations. The application was published for opposition on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

Amorus Pharmaceutical Trademark Application

The USPTO published trademark application TM79441630 for AMORUS covering pharmaceutical goods and medical apparatus including filled syringes, dermatological products, injectable dermal fillers, and related medical instruments. The mark was filed on November 27, 2025 and published on April 1, 2026, opening a standard 30-day opposition period for third parties.

Alcotra Trademark Application - Published for Opposition

USPTO published trademark application TM79419459 for ALCOTRA for opposition, covering goods and services in Classes 1, 3, 4, 5, 33, and 35 including pharmaceuticals, chemicals, alcoholic beverages, fuels, and retail services. The application was filed on 2024-09-24 and published on 2026-04-01.

Probiotic Preparations Trademark Application - Class 5

The USPTO published trademark application TM79441709 for probiotic preparations covering goods in International Class 5 (pharmaceuticals) and Class 3 (cosmetics). The application, filed on November 27, 2025, includes probiotic supplements, medicated preparations, dietary supplements, and bacterial formulations for medical and veterinary use. Publication initiates a 30-day opposition period during which third parties may challenge the registration.

BEAUTY WITHOUT COMPOMPISE Trademark Application - Class 005

The USPTO published trademark application TM79441342 for 'BEAUTY WITHOUT COMPROMISE' in Class 005 (Pharmaceuticals), covering pharmaceutical preparations, sanitary preparations, dietetic substances, and vitamins across 847 units. The application was filed November 28, 2025, and published for opposition on April 1, 2026.

Beautiful Nutrition US trademark application published April 1st

Beautiful Nutrition US trademark application published April 1st

FOLLY Hair Growth Gummy Trademark Published

The USPTO published trademark application TM79441174 for FOLLY, covering dietary and nutritional supplements in gummy form for promoting hair growth and general health and well-being. The trademark was filed on November 27, 2025, and published on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

VOCO MTA VPT trademark published for dental materials

The USPTO published VOCO MTA VPT (Application No. 79440442) for opposition, a trademark for pharmaceutical products and materials for the dental field including dental restoration materials, filling materials, cements, base materials, and capping materials. The application was filed on 2025-11-28 and published on 2026-04-01.

JUCED Trademark - Beverages and Supplements (Class 005)

USPTO published trademark application TM79440005 for "JUCED" covering fruit beverages, vitamin drinks, and dietary supplements under Class 005. The mark was filed on 2025-11-27 and published for opposition on April 1, 2026. No compliance obligations or deadlines result from this publication.

Isotopically enriched psychedelic analogs for brain disorders

The USPTO published patent application US20260092060A1 for isotopically enriched analogs of 2-bromo-LSD, LSD, ALD-52, and 1P-LSD developed by inventors Matthew Duncton and Samuel Clark. The compounds are directed toward treating neurologic and brain disorders. The application was filed on June 5, 2025, under Application No. 19228993.

Broad Spectrum Antiviral Compositions and Methods

The USPTO published patent application US20260092059A1 by Evrys Bio, LLC covering novel thiazole- and isoquinoline-containing compounds for treating broad-spectrum viral infections. The compounds demonstrated inhibition of HCMV, influenza viruses, Zika virus, BK Virus, and RSV in cell-based assays. The application (No. 19342999) was filed September 29, 2025, and published April 2, 2026.

MOLECULE 46 Trademark Registration

The USPTO published trademark application TM79442804 for MOLECULE 46 in Class 5, covering medical genetics services, in vitro diagnostic preparations, and medical testing instruments. The publication initiates the opposition period during which third parties may challenge registration.

MMAFIT Trademark Application Published for Opposition

USPTO published trademark application TM79443328 for MMAFIT on April 1, 2026. The application covers goods and services including dietary supplements, food substances for medical use, clothing, footwear, and fitness-related entertainment services. The publication initiates a 30-day opposition period during which third parties may file objections.

Ricola Trademark Application Published for Opposition

The USPTO published Ricola's trademark application (TM79443437) for opposition on April 1, 2026. The application covers goods in International Class 005, including pharmaceutical products, vitamin supplements, medicinal herbal teas, food supplements, and confectionery. Third parties have a 30-day window to file opposition proceedings.

LUNA trademark published for opposition, medical products

The USPTO published trademark application TM79443850 for LUNA on April 1, 2026. The mark covers sanitary products for medical use including dressing material and teeth filling material. The opposition period is now open for interested parties to challenge the registration.

WET&FORGET Trademark Application Published for Opposition

The USPTO published trademark application TM79444339 for WET&FORGET covering fungicides, pest control preparations, cleaning products, and related maintenance services in International Classes 1, 3, 5, and 37. The trademark application entered the opposition period on April 1, 2026, allowing third parties with standing to challenge registration.

JET BLUE BITE Trademark for Impression Materials

USPTO published the JET BLUE BITE trademark (Serial No. 79443987) for impression materials for dental use. The trademark application was filed on November 28, 2025, and published on April 1, 2026. Third parties have a 30-day opposition period following publication.

Water bottles, tableware, jewelry trademark published Apr 01

Water bottles, tableware, jewelry trademark published Apr 01

HYDROBEEF Protein Trademark Application

The USPTO published trademark application TM79445678 for "HYDROBEEF" covering hydrolyzed animal protein raw materials, protein supplements, protein bars, and protein-enriched beverages. The application was filed on November 27, 2025, and published for opposition on April 1, 2026. Interested parties have a 30-day window to file opposition if they believe registration would cause confusion with existing marks.

Break the Boundaries Trademark - Pharmaceuticals Class 005

USPTO published trademark application TM79442531 for "Break the Boundaries" covering pharmaceutical information services, medical research including gene therapy and stem cell services, clinical trials, SaaS/cloud platforms, and medical equipment rentals under Class 005. The application was published April 1, 2026, initiating the standard opposition period.

Methods and Systems for Ablation of the Renal Pelvis

Verve Medical, Inc. filed a patent application (US20260091000A1) with the USPTO on April 2, 2026 for methods and systems of renal pelvis ablation to treat renal nerves. The application covers apparatus and systems for delivering heat or extracting heat through the renal pelvis wall, or delivering active substances to ablate tissue lining. Inventors include Terrence J. Buelna, Adam Gold, and Rahul Rao.

Heating Garment Patent Application

USPTO published patent application US20260090910A1 for a heating garment filed by REB LLC (inventor: Katelyn Bray). The garment includes multiple heating elements disposed between two material layers with coupling mechanisms. CPC classifications indicate thermal therapy applications (A61F 7/02, A61F 7/007).

Treatment apparatus and method for ophthalmological laser refractive index change control data

USPTO published patent application US20260090916A1 for a treatment apparatus and method providing control data for an ophthalmological laser to generate laser-induced refractive index changes. The invention involves determining irradiation positions using first and second laser pulse lengths, with the first being shorter than the second, and providing control data including adjusted pulse lengths for preset irradiation positions.

Adjustable Shunts with Improved Flow Control

The USPTO published patent application US20260090914A1 for adjustable shunting systems with improved flow control, filed by inventors David Batten and Tessa Bronez. The application (No. 19120217) was filed November 1, 2023 and published April 2, 2026. The technology involves apertures in flexible membranes that flex into wells or empty spaces to improve sealing.

Face Masks with Therapeutic Cooling Patent Application

The USPTO published patent application US20260090909A1 for a face mask configured to provide therapeutic cooling using thermoelectric cooling devices such as Peltier elements. The invention generates heat flux at material junctions, creating cold and hot areas, with the cold side positioned toward the user's face. Inventors include Hannah Elizabeth Clark, Olivia Louise Parsons, Christopher W. Hedges, Christina J. Crowley, and Ellen Catherine Padula.

Ophthalmic Laser Treatment Apparatus

USPTO published patent application US20260090915A1 for an ophthalmic laser treatment apparatus developed by four inventors from Japan. The invention features a laser irradiation optical system combined with an observation system that includes an internal display unit allowing operators to view images through an eyepiece lens. Application No. 19339333 was filed September 25, 2025.

Implant Insertion Device for Puncta and Other Orifices

The USPTO published patent application US20260090913A1 by inventor Martin O'Malley for an implant insertion device designed for delivering implants or other payloads to the canal of a patient via orifices such as puncta. The application claims priority to European application 19338201 and includes embodiments with barrel, tip, plunger, and alignment pathway features for controlled payload delivery.

Low Power Electronic Ocular Implant with Multiple Imaging Systems

USPTO published patent application US20260090912A1 for a low-power electronic ocular implant with multiple imaging systems. The device includes imaging systems to receive incoming light and projection systems that simultaneously project different images to different retinal regions at varying resolutions to minimize power consumption. Inventors: Wayne H. Woods Jr., Alexander J. Melville, Christopher Shelby. Application No. 19341757.

Ophthalmic insertion tool patent with integral scleral marker

USPTO published patent application US20260090911A1 by inventor James T. Perkins, covering an ophthalmic insertion tool with integral scleral marker. The application describes a device including a housing, cannula with distal tip and lumen, retractable sheath, and scleral markers positioned at distal and/or proximal ends of the housing. Application No. 18903180 was filed October 1, 2024.

Personal Temperature Regulating Device and Wearable Garment

USPTO published patent application US20260090908A1 for a personal temperature regulating device comprising a wearable garment with an integrated temperature regulating membrane and control module. Inventors Michael Leland Frost and Adam Jacob Frost filed the application on September 25, 2025. The technology is classified under CPC A61F 7/007 and relates to personal thermal management systems.

Laser Energy Control System with Interworking Control Scheme

USPTO published patent application US20260090917A1 for a laser energy control system invented by David Jung. The system includes a controller configured to communicate with a laser system using an interworking control scheme and receive inputs from an input device for laser control. The application was filed September 16, 2025, and published April 2, 2026.

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of PRC2 inhibitor compounds for cancer treatment. Inventors: Mohammad AL-SAYAH and Robert Ronald MILBURN. Application filed September 13, 2023, classified under C07D 487/04 (heterocyclic compounds - organic chemistry). The patent covers the physical forms, pharmaceutical compositions, and methods of treating cancer by administering the compound.

Heterocyclic Compounds for Treatment of Disease

USPTO published patent application US20260092064A1 for heterocyclic compounds and compositions for treating disease, filed by inventors Raju Mohan, John Nuss, and Jason Harris on May 14, 2025. The application was published April 2, 2026, covering compounds classified under CPC codes including C07D 471/04, A61K 31/41, and A61P therapeutic categories.

Seven inventors file PROTAC protein degradation compounds patent

Seven inventors file PROTAC protein degradation compounds patent

Pyridine Carboxamide Compounds for Treating Medical Conditions

The USPTO published patent application US20260092062A1 for pyridine carboxamide compounds and their use in treating medical conditions. The application was filed by inventors Todd Bosanac, Nathan Oliver Fuller, Robert Owen Hughes, Guy Bemis, and Janeta Valentina Popovici Muller on September 26, 2023, and published on April 2, 2026.

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.

Novel synthetic routes for macrocyclic heterocycle manufacturing

USPTO published patent application US20260092066A1 on April 2, 2026, disclosing novel synthetic methods for preparing macrocyclic heterocycle intermediates. The application (filed June 18, 2025, Application No. 19242506) covers efficient methods for synthesizing key intermediates in the preparation of Compound (I) with broad substituent applicability.

Method for Preparing Amidines from N-(alkyl lactams) via Dehydration Catalysis

USPTO published patent application US20260092067A1 disclosing a method for preparing amidines from N-(amino-alkyl) lactams via dehydration using heterogeneous catalysts including cerium oxide, boron phosphates, zirconium compounds, and phosphotungstic acid. The application (No. 19108987) was filed September 4, 2023 and published April 2, 2026, listing inventors Nicola Vecchini and Federico Mondini. This represents a new synthetic route for amidine compounds used in pharmaceutical and fine chemical synthesis.

Modular Headgear for Patient Airway Interface

Gerard Michael RUMMERY filed USPTO Patent Application US20260091191A1 for a modular headgear system for patient airway interfaces that deliver positive pressure therapy. The invention includes nasal and mouth cushion configurations with positioning structures and specialized headgear clips at varying angles. Application was published April 2, 2026.

Methods and User Interfaces for Application-Based Transitions

USPTO published patent application US20260091194A1 covering health application user interfaces with animated interactive graphical objects and virtual transitions. Inventors Jonathan PERRON, Jordan A. CAZAMIAS, and Ryan HOBACK filed Application No. 19224487 on May 30, 2025, which published on April 2, 2026. CPC classifications include A61M 21/02 and G06F 3/011.

Non-Invasive Cognitive Device with Electromagnetic Disc Behind Ear

USPTO published patent application US20260091193A1 for a non-invasive cognitive device featuring a small electromagnetic disc positioned behind the user's right ear. The device pairs with a monitoring system and transmits electromagnetic signals with music directly to the brain to ease symptoms of dementia, depression, Alzheimer's, and anxiety. Inventors: Alicia Catbagan-Tapiador and Arlene Rivera.

Nitric Oxide Treatment Methods for Bronchiectasis with Nontuberculous Mycobacteria

USPTO published patent application US20260091192A1 by inventors James Potenziano and Christopher Miller for methods of treating patients with nontuberculous mycobacteria by administering nitric oxide for at least 100 days to increase functional capacity and quality of life. The application (No. 19413816) was filed December 9, 2025, and published April 2, 2026.

Removal-resistant tracheostomy tube securement device patent

The USPTO published patent application US20260091189A1 filed by inventors Michael Szeliga and Hayley Sweetser for a removal-resistant securement device for tracheostomy tubes. The device includes an enlarged shield portion and laterally disposed strap portions with mechanical fasteners designed to reduce pressure on skin and prevent accidental decannulation. Application No. 19321574 was filed September 8, 2025.

Temperature-controllable wire in tracheostomy tube changes diameter

The USPTO published patent application US20260091190A1 for a tracheostomy tube structure featuring a temperature-controllable deformable wire embedded in the tube wall. The wire changes diameter in response to temperature, allowing insertion at reduced diameter and subsequent expansion to facilitate breathing and reduce sputum accumulation. Inventors include Pai-Chien Chou, Chien-Hua Chen, Hsueh-Lien Su, and Ya-Ting Juang.

Medical Wire with Flexible Tube and Operation Wire

USPTO published patent application US20260091198A1 for a medical wire assembly including a bendable flexible tube extending front-to-rear, an operation wire inserted within the tube, and a support fixed to the rear end of the tube. The operation wire front end is fixed to the tube front end while displaced radially from the central axis in one direction.

Multi-lumen catheters for fluid delivery

USPTO published patent application US20260091197A1 for multi-lumen catheters and related systems by Cerinfuse Technologies, Inc. The invention covers size-adjustable catheters with guide and fluid lumens, adapter ports, and methods for fluid delivery to tissue or cavities. The application was filed on September 30, 2025.

Provisioning device for storing and transporting catheters

The USPTO published patent application US20260091196A1 for a provisioning device designed to store and transport catheters, specifically balloon catheters for percutaneous transluminal coronary angioplasty. The application, filed by inventors Eberhard Engelien, Fred Held, Verena Desch, and David Rieche, describes a support with holding elements arranged to secure a catheter rolled in an annular manner. Medical device manufacturers developing catheter-related products should review the published claims for potential overlap with existing or planned products.

Intermittent Intravesical Therapeutic Administration System

USPTO published patent application US20260091195A1 for an intermittent intravesical catheter system featuring a dual-lumen design with urinary and instillation lumens, drainage and instillation eyelets, and a slidable sheath for switching between drainage and therapeutic instillation modes. Inventors: Howard Shapland, Scott Glickman, Gabriel Korn. Application No. 19289334.

On-Demand Biospecimen Collection System

The USPTO published patent application US20260094679A1 filed by inventor Patricia Tawadros for a computer-implemented system enabling secure, de-identified coordination among donors, scientists, and administrators for human biospecimen collection. The platform integrates donor registration, identity verification, scheduling, payment processing, and real-time courier tracking with configurable compensation models.

Radiology Report Generation Using AI Segmentation and Speech-to-Text

USPTO published patent application US20260094682A1 for a system and method of automatically generating radiology reports using AI. The invention processes medical images through segmentation and classification models, incorporates radiologist speech input converted via NLP, and generates structured reports with annotations. The patent names inventors Nivedha Srinivasan and Mouleeswaran Kumar, with application number 18901905.

Functional Behavior Assessment and Positive Behavior Support Strategy Method and Device

The USPTO published patent application US20260094683A1 for a computer-implemented method and device that administers functional behavior assessment (FBA) and generates positive behavior support (PBS) strategies. The system collects target behavior problems, generates questionnaires, determines probable behavior functions, and creates customized lesson plans. Inventors include Hui-Ting Wang, Jia-Yin Wang, Fang-Yu Lin, and Jia-Chi Liang.

Medical Card System with UV Code and Embedded Chip for Healthcare Information Management

The USPTO published patent application US20260094681A1 by inventor Richard Schriewer, covering a system for managing patient medical information comprising a medical identity card with multiple data storage layers (visible print, UV-visible code, and embedded chip), a mobile UV reader for healthcare personnel, and a stationary reader with security controls for clinical settings. The system enables tiered access to healthcare data based on sensitivity levels.

Pupillary biomarkers method assesses psychotropic drug effectiveness

USPTO published patent application US20260094684A1 for a method of assessing psychotropic drug effectiveness using pupillary biomarkers. The method uses a pupilometer to obtain and compare pupillary data before and after drug administration, displaying an output indicating drug effectiveness. Inventors: Kamran Siminou, Claudio Privtera, Jeffrey Oliver. Application No. 18898899.

ALT-803 IL-15 Soluble Fusion Molecules and Methods

The USPTO published patent application US20260092097A1 for ALT-803, a complex of interleukin-15 (IL-15) superagonist mutant and dimeric IL-15 receptor α/Fc fusion protein. The application covers compositions and methods for enhancing immune response against neoplasia (multiple myeloma, melanoma, lymphoma) or viral infections (HIV). Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han. Application filed June 25, 2025.

Methods for Generating Hematopoietic Progenitor Cells

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

Pepmixes for Multiviral CTL Generation

USPTO published patent application US20260092256A1 by Baylor College of Medicine covering methods of generating CTLs (cytotoxic T lymphocytes) targeting antigens from multiple viruses. The invention uses peptide mixtures exposed to PBMCs with IL4 and IL7 expansion. Published April 2, 2026, Application No. 19020866.

Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells

The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.

Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 for serotype-specific cell-based assays used in characterizing Clostridia botulinum neurotoxins. The assays utilize genetically modified cells capable of discriminating between different serotypes of clostridium neurotoxins without requiring serotype-specific neutralizing antibodies or competing heavy chains. Inventors: Ward Tucker, Francis Mark Dunning, Tim Piazza. Application No. 18920316.

Methods of Recellularizing Tissue Transplant for Improved Transplantability

The USPTO published patent application US20260092253A1 for methods of recellularizing an organ or tissue matrix for improved transplantability. Inventors are Doris A. Taylor and Stefan M. Kren. The application was filed December 9, 2025, under application number 19413394. This publication provides public notice of the pending patent application but does not grant any patent rights.

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Engineered cytokines, AI-designed polypeptides, pharmaceutical compositions

The USPTO published patent application US20260092094A1 disclosing engineered cytokines, AI-designed polypeptide structures with modulated stability, potency and developability, and pharmaceutical compositions for therapeutic use. The application, filed May 3, 2024 under Application No. 19481848, covers in silico methods using artificial neural network machine learning protocols and molecular dynamics simulations for engineering cytokines.

IL-18 Variant Polypeptides for Therapeutic Use

USPTO published patent application US20260092093A1 on April 2, 2026, disclosing engineered IL-18 variant polypeptides with mutations at positions G3, E6, D54, N91, C38, C68, C76, D98, S117, and C127. The variants demonstrate enhanced IL-18Rα binding and reduced IL-18BP binding compared to wild-type human IL-18 (SEQ ID NO: 1). Inventors include Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, and Fan LIU, with original filing dated September 6, 2023.

TNF-alpha Variant Fusion Molecules

USPTO published patent application US20260092092A1 for TNF-alpha variant fusion molecules and their therapeutic uses. Inventors include Robin Allene Aglietti, Susannah Dale Barbee, Peter Michael Bowers, and Melanie Angelika Kleinschek. Application No. 19294212 was filed on 2025-08-07.

Novel CXC receptor ligands from GCP2

USPTO published patent application US20260092091A1 for novel polypeptide ligands of CXCR1 and/or CXCR2 derived from GCP2. The application (No. 19120219) was filed October 11, 2023, by inventors Kouvatsos, Day, Dell'Accio, and Caxaria. The invention covers polynucleotides encoding the ligands, compositions, and uses thereof.

NGF Mutein Production Process Patent Application

Chiesi Farmaceutici SpA filed USPTO patent application US20260092090A1 on April 2, 2026, for a process producing nerve growth factor (NGF) and muteins at high purity from recombinant sources. The muteins may exhibit improved detectability and reduced nociceptive activity compared to wildtype human NGF. Application No. 19265384 was filed July 10, 2025.

Interleukin-2 for Treating Autism Spectrum Disorder

USPTO published patent application US20260092095A1 by INSERM covering interleukin-2 (IL-2) for treating autism spectrum disorder (ASD). The application also extends to preventing ASD in at-risk children or through maternal administration during pregnancy. Assignee is INSERM (Institut National de la Santé et de la Recherche Médicale, France).

Recombinant Vaccine Against Helminths in Pichia pastoris

USPTO published patent application US20260092089A1 by Fundação Oswaldo Cruz disclosing recombinant production of Sm14 Schistosoma mansoni vaccine antigen using genetically engineered Pichia pastoris strains with methanol-inducible (AOX1) and constitutive (GAP) promoters. The application covers synthetic gene construction, fermentation processes, and protein purification methods scalable for industrial vaccine manufacturing.

Method of Making a Pharmaceutical Composition Comprising a p80 Protein

USPTO published patent application US20260092087A1 by Prime Bio, Inc. covering a method for producing recombinant p80 polypeptide using E. coli culture with L-Arabinose induction. The p80 protein functions as a tight junction modulator to enhance intestinal permeability for therapeutic agents. The application (No. 19352451) was filed October 7, 2025.

Variant Anti-Viral Polypeptides

The USPTO published patent application US20260092088A1 for variant lectin anti-viral polypeptides filed by inventors Cristina BONGIORNI, Mai DU, David A. ESTELL, Keith FROGUE, Amy Deming LIU, and Darshana KADEKAR. The application covers engineered anti-viral lectin compositions for treating and preventing viral diseases in animals, with a filing date of September 19, 2023.

Surgical Robot System and Flexible Surgical Instrument

USPTO published patent application US20260090853A1 filed by Beijing Yunlijing'an Technology Co., Ltd. for a surgical robot system and flexible surgical instrument. The invention includes a flexible instrument with spiral accommodating grooves for storing actuator units and a transmission substrate connected to an instrument driving apparatus. Filing date was March 24, 2023.

Oncolytic Herpes Virus Cancer Therapy Vectors

USPTO published patent application US20260091069A1 for an oncolytic herpes simplex virus vector with dual transcriptional and translational control for cancer therapy. The vector incorporates modified ICP27 and ICP34.5 genes under CEA promoter and miRNA-124/143 control respectively, and includes a virus-expressed cytokine cassette encoding IL-12 and IL-15/IL-15RA. Inventors include William Wei-Guo Jia, Dmitry V. Chouljenko, and six others.

TSLP Treatment Using Oligonucleotide siRNA and ASO Compositions

The USPTO published patent application US20260091053A1 disclosing oligonucleotide compositions (siRNA and antisense oligonucleotides) targeting Thymic Stromal Lymphopoietin (TSLP) for treatment of TSLP-related diseases. The application covers methods of treating airway disorders by administering oligonucleotides specific to the long isoform of TSLP. Inventors include Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, and David Rozema. The application was filed on May 19, 2025.

MicroRNA from Rhodiola for Fibroplasia Treatment

USPTO published patent application US20260091052A1 filed by Beijing Baishihekang Pharmaceutical Technology covering microRNA derived from Rhodiola root for prevention and treatment of fibroplasia medical signs and syndromes. The application (No. 19319016) was filed September 4, 2025 and published April 2, 2026, listing five inventors including Chengyu Jiang and Jianchao Du. CPC classifications indicate pharmaceutical compositions and nucleic acid technologies.

Methods for Improving Cognitive Function Using ILC2 Cranium Implants

The USPTO published patent application US20260091063A1 by Albany Medical College covering methods to improve cognitive function by implanting activated group-2 innate lymphoid cells (ILC2) into a subject's cranium. The application also discloses methods using cytokines including IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin to treat aging-associated cognitive decline. Assignee: Albany Medical College; Inventors: Qi Yang; Application No. 19335390.

Muscarinic M1 Receptor Compound Treats Alzheimer Disease

USPTO published patent application US20260092052A1 for a nitrogen-containing heterocyclic compound functioning as a muscarinic M1 receptor positive allosteric modulator. The compound is intended for prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, and dementia with Lewy bodies. Inventors include Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, and Makoto Kamata. Application No. 19010914 was filed on January 6, 2025.

Chemokine receptor modulators and C07D heterocyclic compounds patent application

USPTO published patent application US20260092050A1 for chemokine receptor modulators and C07D heterocyclic compounds. The application discloses novel compounds for modulating chemokine receptor activity with potential therapeutic uses. Inventors include Parcharee Tivitmahaisoon, David J. Wustrow, Mikhail Zibinsky, and Omar Robles. Filing date was January 17, 2025.

Methods of Making Trans Isomeric Forms of G Protein-Coupled Receptor Modulators

The USPTO published patent application US20260092049A1 disclosing methods for synthesizing trans isomeric forms of G protein-coupled receptor (GPCR) modulators with high trans isomeric purity. The application names eight inventors and covers pharmaceutical compositions and synthetic routes for producing these receptor modulators. This publication establishes priority rights for the claimed invention under 35 U.S.C.

Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof

USPTO published patent application US20260092055A1 by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives useful as LpxC inhibitors for treating bacterial infections. The application covers the chemical compounds, preparation methods, and pharmaceutical compositions. Application No. 19112826 was filed September 28, 2023.

Melanocortin-4 Receptor Agonists for Obesity and Diabetes Treatment

The USPTO published patent application US20260092056A1 for melanocortin-4 receptor agonists developed by eight inventors. The compounds of Formula 1 demonstrate agonist activity against melanocortin-4 receptors and may be useful in preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.

BCL-XL/BCL-2 Degraders and Uses Thereof

The USPTO published patent application US20260092057A1 for BCL-XL/BCL-2 degrader compounds and methods of using the same for treating conditions such as cancer. The application was filed on May 12, 2023, by inventors including Huijun Dong, Bin Yang, and others, and covers novel chemical compositions under CPC classifications including C07D 417/12, C07D 471/04, and related therapeutic uses.

Small Molecule Degraders and Fluorescent Probes of PXR

USPTO published patent application US20260092058A1 disclosing compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention relates to decreasing adverse drug reactions associated with administration of anticancer agents, antibacterial agents, non-steroidal anti-inflammatory agents, or anticonvulsant agents. Application No. 18902844 was filed September 30, 2024.

Fused Ring STAT6 Inhibitor for Atopic Dermatitis Treatment

The USPTO published patent application US20260092054A1 disclosing a fused ring compound with STAT6 inhibitory activity for treating atopic dermatitis and allergic diseases. Invented by Yoshitake Sumikawa, Issei Akahoshi, and Masaya Kato, the application (No. 19116232) was filed September 29, 2023 and published April 2, 2026. The claimed compound and pharmaceutical compositions target inflammatory conditions via STAT6 pathway inhibition.

KHK Inhibitor Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092053A1 for KHK (ketohexokinase) inhibitor heterocyclic compounds, filed August 22, 2025. The application includes nine inventors and covers compounds of a specified formula with variable substituents defined in the specification. The compounds are classified under multiple CPC categories including C07D 409/14, C07D 401/14, and related pharmaceutical compound classifications.

Pyrimidine Compounds for Cancer Prevention Treatment

The USPTO published patent application US20260092051A1 for pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers. Inventors include In Hwan Bae, Ji Sook Kim, Jae Yul Choi, and others. The application (No. 19203828) was filed on May 9, 2025, and published on April 2, 2026. This is an informational publication with no compliance requirements.

Coordinated movement control of robotic surgical tools

USPTO published patent application US20260090855A1 by inventor Alexander Tarek Hassan for a robotic medical system enabling coordinated movements of robotic surgical tools through multiple ports while maintaining remote centers of motion. The system provides three control modes for managing camera and tool coordination during surgical procedures, with automatic movement capabilities to keep tools within camera field of view.

Medical Lighting Device for Surgical Diagnostic Use

USPTO published patent application US20260090857A1 by inventors Joonheon Kim and Won Suk Choi for a medical lighting device comprising a frame, light arm, and multiple lamp modules with angle adjusting devices for surgical diagnostic use. The application (No. 19411073) was filed December 5, 2025.

Eye tracking display control surgical technique monitoring

USPTO published patent application US20260090858A1 for a surgical hub system that monitors user visual gaze to control display priority. The system uses contextual data to determine surgical tasks, analyze technique performance against baselines, and trigger corrective actions including display adjustments and medical instrument parameter changes.

Medical device chuck with rotating fiducial marker array patent

The USPTO published patent application US20260090859A1 for a medical device chuck with a rotating fiducial marker array. Inventors Jesse Harrison Gallant, Osamah Choudhry, Christopher Morley, and Florentin Jonas Liebmann filed the application on September 27, 2024. The invention enables precise positioning and tracking of medical devices during surgical procedures by maintaining fixed distances between fiducial markers and the device tip.

Robotic Collision Boundary Determination for Surgical Systems

The USPTO published patent application US20260090856A1 for Auris Health, Inc., covering techniques for determining collision boundaries for robotic arms in surgical systems. The invention relates to controlling robotic arm movement based on detected regions near objects in the surgical environment. Application No. 19411024 was filed December 5, 2025.

Magnetically Couplable Fiducial Marker Arrays for Surgical Navigation

USPTO published patent application US20260090861A1 for a magnetically couplable fiducial marker array designed for surgical navigation. The invention includes a rigid body supporting multiple surgical fiducial markers in an asymmetrical fixed arrangement, with a magnetic coupling mechanism for attachment to a surgical spinous process clamp. Inventors include Jesse Harrison Gallant, Osamah Choudhry, Christopher Morley, and Florentin Jonas Liebmann.

Pivotable Medical Device Clamp

The USPTO published patent application US20260090862A1 for a pivotable medical device clamp invented by Jesse Harrison Gallant et al. The invention comprises a main body with rotating arm arrangements and a traveling nut mechanism that clamps onto cylindrical portions of surgical devices such as pedicle probes, providing secure lateral fixation while permitting axial rotation. A clamp coupling component can also attach a rotatable fiducial marker array.

Rotatable Fiducial Marker Array for Surgical Navigation

The USPTO published patent application US20260090860A1 for a rotatable fiducial marker array designed for surgical navigation. The application, filed September 27, 2024, covers a rigid body supporting fiducial markers in an asymmetrical arrangement with multiple array arms extending from a central region, including a coupling arrangement enabling rotation and locking at fixed positions. Inventors include Jesse Harrison Gallant, Osamah Choudhry, Christopher Morley, and Florentin Jonas Liebmann.

Intuitive Surgical modular control shell for surgical robotics

Intuitive Surgical modular control shell for surgical robotics

Neurovascular Stent Delivery Apparatus

ACCUMEDICAL BEIJING LTD. has published patent application US20260090901A1 for a neurovascular stent delivery apparatus configured for selectively positioning self-expanding stents at target sites. The application, filed October 1, 2024, covers a delivery mechanism with self-expanding sleeves, proximal and distal end caps, and an engagement mechanism with stent catch for removable stent engagement. Inventors include Tai Dac Tieu, Zihao Luo, and Kirk Wu.

Volitional EMG controller for powered knee prosthesis

The USPTO published patent application US20260090900A1 for a volitional EMG controller system for powered knee prostheses, enabling users to climb stairs using signals from muscles like the biceps femoris. Inventors include Tommaso Lenzi, Suzi Creveling, and Lukas R. Gabert, with application filed October 15, 2025.

Telemetry trial device for smart medical implants

USPTO published patent application US20260090899A1 for a trial fitting device for smart medical implants. The application, filed July 17, 2025, covers devices and methods including a handle, shaft, rotating head portion, rotational indicator, and telemetry gauge configured to indicate threshold distance. Inventors include Kevin T. Foley, Steven D. Glassman, Adam D. Glaser, and Newton H. Metcalf Jr.

Femur preparation for prosthetic hip stem component

Femur preparation for prosthetic hip stem component

Bruxism Treatment Device with Golf Club Shape

The USPTO published patent application US20260090907A1 for a bruxism treatment device invented by Andrea Morris. The device comprises a main body resembling a flattened golf club head with a treatment arm and knob element, designed to discourage tooth-grinding during sleep by producing discomfort when fully biting down.

Anti-snoring device patent with adjustable connectors and guiding rods

USPTO published patent application US20260090906A1 for an adjustable anti-snoring device featuring two side pieces, upper and lower curved structures, and connectors with guiding rods and adjusting screws for adjustment. Inventor Allen Sue-Lin TONG filed the application on May 6, 2025 (Application No. 19199395). The device is classified under CPC A61F 5/566.

Bilateral tongue base repositioner

USPTO published patent application US20260090905A1 for a bilateral tongue base repositioner invented by John Summer. The device comprises an upper oral appliance with lateral tongue base contacting pads and a wire framework that adjusts tongue position via apertured positioning plates. The invention is classified under CPC A61F 5/566 and appears intended for treatment of obstructive sleep apnea through tongue base repositioning.

External Fecal Management System and Wearable Device

USPTO published patent application US20260090904A1 for an external fecal management system comprising a wearable guardian vessel device with border cushion, reservoir well portion, interior tube with suctioning port and fenestration openings, and mesh layer. Invented by Carly Googe. Application No. 19347495 filed October 1, 2025.

External Ankle Brace with Upright Extensions for Restricting Movement Direction

The USPTO published patent application US20260090903A1 for an external ankle brace featuring rigid heel enclosure with lateral and medial upright extensions that selectively restrict or permit ankle movement in different directions. The invention by inventors Michael W. Bean and Frederick John Ferlic includes pivot prevention features for the upright extensions. The application was filed August 29, 2025.

Pharmaceutical Compositions Comprising Maralixibat and Uses Thereof

The USPTO published patent application US20260090993A1 by Mirum Pharmaceuticals, Inc. for pharmaceutical compositions comprising maralixibat as an active ingredient. The application covers the use of these compositions as solid dosage drug products for treating cholestatic pruritus and cholestatic liver disease. The application was filed on April 9, 2025, and contains 8 CPC classifications related to drug formulations.

Hydroxypropyl methylcellulose powder compositions and applications

USPTO published patent application US20260090992A1 for homogenized hydroxypropyl methylcellulose powder compositions containing chemical signaling agents and optionally biologically active agents, with particle diameters of 20-500μm. Inventors: Todor A. Popov and Peter David Josling. Application No. 19409272 was filed December 4, 2025.

Fat tissue drug delivery system for cancer treatment

USPTO published patent application US20260090990A1 for a fat tissue-based drug delivery system designed for cancer treatment. The invention comprises fat tissue or derivatives thereof for delivering molecules, preferably antitumor drugs. The application (No. 19307845) was filed August 22, 2025, with inventors including Augusto Pessina, Giulio Alessandri, Carlo Tremolada, and Offer Zeira.

Pouch Dispensing System for Topical Anesthetic

USPTO published patent application US20260090987A1 for a pouch dispensing system for topical anesthetic. Invented by Andrew Albee, the application (No. 19347190, filed 2025-10-01) covers an apparatus including a pouch, cover material, and topical anesthetic for oral application.

Tablet Formulation Patent for HIV Capsid Inhibitor and NRTTI

The USPTO published patent application US20260090994A1 for tablet formulations combining an HIV capsid inhibitor with a nucleoside reverse transcriptase translocation inhibitor (NRTTI) for treating HIV infections. The application was filed on August 29, 2025 under Application No. 19314157. Inventors include Benjamin Chal, Jay Poorna Reddy, Dhananjay Devidas Marathe, and eight others.

Fluid-Driven Mechanical Ventilator with Accumulator

The USPTO published patent application US20260091187A1 for a fluid-driven mechanical ventilator system with an accumulator featuring oscillating flow control. The invention, filed by inventor David A. Dzioba (Application 19342550), includes a bi-directional flow controller, respiratory interface, and displaceable diaphragm chamber design for ventilation delivery.

Medical Gas Delivery System Patent Application

USPTO published patent application US20260091186A1 for a medical gas delivery system including a positioner with aperture for receiving a diffuser, designed for delivering supplemental oxygen to patients. Inventors Anthony and Aaron Esplin filed the application on September 29, 2025. The system includes a pillowcase with fasteners to secure the positioner and diffuser over a pillow.

Home Ventilator with Air Purification System

USPTO published patent application US20260091185A1 for a home ventilator system featuring integrated air purification. The invention includes a body with respiratory function assembly, storage device, air purification system, and display control component. Inventors: Lian CHEN, Zhiliang CHEN, Xuwu YANG, and Sheng CHEN. Application filed September 25, 2025.

Endoscopic Airway Device with Esophageal Cuff

USPTO published patent application US20260091188A1 for an endoscopic airway device invented by Kevin Chong Kim. The device features an outertube with scope channel, an esophageal cuff for securing the device and preventing gastric reflux, and an inflatable bladder to create an unobstructed air passage to the trachea.

Patent US20260091179A1 for vapor system with detection

Patent US20260091179A1 for vapor system with detection

Gas Delivery Hose Hook and Ventilator Support Device

USPTO published patent application US20260091184A1 for a gas delivery hose hook and ventilator support device invented by Jie Peng. The invention relates to medical devices for respiratory therapy, featuring a hook mechanism with limit ribs for securing gas delivery hoses. Application filed September 29, 2024, published April 2, 2026.

Clean Storage System for Home Ventilator

The USPTO published patent application US20260091183A1 for a clean storage system for home ventilators invented by Lian Chen, Zhiliang Chen, Xuwu Yang, and Sheng Chen. The system includes a body with a ventilator placement region, storage device with exhaust ports, air purification system with fan and filtration, and display controls. Application No. 19338323 was filed September 24, 2025, and published April 2, 2026. This is a standard patent publication with no regulatory compliance requirements.

Metered Dose Inhalers of Fluticasone or an Ester Thereof

The USPTO published patent application US20260091182A1 for a metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its ester. The application, filed December 5, 2025, with six named inventors, covers the composition, manufacturing process, and use in treating respiratory disorders including asthma. The invention includes a canister with metering valve, actuator, and dose counter.

Improved Stem Block Inhaler with Superior Atomization Efficiency

USPTO published patent application US20260091181A1 for an improved stem block inhaler with superior atomization efficiency. The application (filed September 26, 2023, Application No. 19114843) names five inventors: David Joseph Rodney, Patrick Lehoux, Mitchell Thompson, Michael Lerer, and Angelo Psellas. The invention relates to stem block designs for metered-dose inhalers that improve aerosol delivery through axially aligned passage, expansion chamber, and exit orifice configurations.

Drug Supply Unit for Inhalation Device

USPTO published patent application US20260091180A1 for a drug supply unit (23) for an inhalation device (50) invented by Stephen T. Dunne, Axel Fischer, and Tobias Kolb. The invention comprises a cartridge (1) containing a drug formulation solution (12) arranged within a housing (22) that is displaceable in a longitudinal direction, with a septum needle (26) that pierces the cartridge septum when in the active position and a releasable lock (34) to hold the cartridge in a passive position.

Dual Target Binding Peptide Composition for Active Targeting DDS

USPTO published patent application US20260092084A1 by MESCUE-JANUSYS INC. for a dual target-binding peptide composition with hydrophilic and hydrophobic regions for active targeting drug delivery systems. The application (No. 18876803) was filed June 23, 2023 and published April 2, 2026.

Vancomycin Derivatives with Siderophore Modification as Novel Antibiotics for Gram-Negative Bacteria

Research Triangle Institute filed USPTO patent application US20260092083A1 on April 2, 2026, disclosing novel vancomycin derivatives with siderophore modification designed as antimicrobials against Gram-negative bacteria including Acinetobacter baumannii and Escherichia coli. The application, filed March 6, 2024 under Application No. 19162234, covers compounds for treating antimicrobial-resistant infections.

Antimicrobial peptide Halymorin variants and methods of using the same

USPTO published patent application US20260092082A1 by Antinbio, Inc. disclosing antimicrobial peptide Halymorin variants comprising amino acid sequences SEQ ID NOs: 2-12. The peptides demonstrate antimicrobial activity against Gram-negative bacteria including Campylobacter jejuni, Escherichia coli, Salmonella Typhimurium, and Klebsiella pneumoniae. Applications cover pharmaceutical compositions, food additives, cosmetics, and hygiene products, as well as methods for treating bacterial infectious diseases.

Saposin-A Derived Peptides with Anti-Angiogenic Activity for Tumor Treatment

The USPTO published patent application US20260091079A1 by Children's Medical Center Corporation covering Saposin-A derived polypeptides with anti-angiogenic activity. The peptides consist of 9 or fewer amino acid residues containing the active core sequence DWLP. The disclosed invention can be used to inhibit tumor growth and cancer metastasis.

Anti-GCC Antibodies and CARs for Immunotherapy

USPTO published patent application US20260091061A1 disclosing anti-GCC single domain antibodies and chimeric antigen receptors (CARs) for cancer immunotherapy. The application, filed September 28, 2023, names Xiaohu Fan, Panglian Xu, Qiuchuan Zhuang, Min Wei, Jiangjing Tang, Chenchen Zheng, and Xu Fang as inventors. This publication does not create any immediate regulatory obligations.

Antigen Receptors and Uses Thereof

USPTO published patent application US20260091060A1 by Holger Voss et al. covering recombinant antigen receptors and engineered T cells for disease treatment. The application (No. 18905085) was filed October 2, 2024 and published April 2, 2026. The invention relates to treating diseases by targeting cells expressing specific antigens using engineered T cell therapy.

Oligopeptide Inhibits Angiogenesis and Vascular Function

The USPTO published patent application US20260091078A1 covering an oligopeptide composition of 3-7 amino acids that inhibits angiogenesis and vascular function. The oligopeptide comprises defined sequence patterns with basic, small, polar, and hydrophobic amino acid residues. The application claims priority from July 7, 2020.

Fc-IL2 variant cancer therapy combination patents

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

Synthetic Triplex Peptide Nucleic Acid-Based Inhibitors for Cancer Therapy

The USPTO published patent application US20260092085A1 by inventors Bahal, Dhuri, and Slack disclosing novel peptide nucleic acid (PNA) oligomers designed to target microRNA-155 (miR-155) for cancer therapy. The application demonstrates in vivo efficacy in xenograft mouse models showing reduced tumor growth. The PNA oligomers form PNA/RNA/PNA triplex structures when binding target RNA sequences.

Cyclic Prosaposins Peptides and Uses Thereof - Cancer Treatment

USPTO published patent application US20260091083A1 filed by Children's Medical Center Corporation for cyclic prosaposin peptides used in cancer treatment and inflammatory diseases. The application (No. 19186486) was filed on April 22, 2025, and published April 2, 2026, naming Randolph S. Watnick as inventor.

Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment

USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.

BacPROTACs for Targeted Protein Degradation in Bacteria

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

Coronavirus Vaccine Nucleic Acid LNP Patent

USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.

Macrophage targeting drug conjugates with mannose linker

The USPTO published patent application US20260091117A1 for macrophage targeting drug conjugates developed by P.I.F. Entrepreneurs Ltd. The conjugates comprise a drug moiety, mannose moiety, and linker (hydrazone or oxime group) for targeted therapeutic delivery. Application No. 19411275 was filed December 7, 2025.

Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment

The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.

Multifunctional drug delivery system for cancer treatment antibodies

USPTO published patent application US20260091125A1 for a multifunctional drug delivery system using inorganic core particles conjugated to antibodies for cancer treatment. The system delivers distinct immunoglobulins to cancerous cells and tissues outside the brain via four-linker architecture. Application filed January 12, 2023; granted Application No. 18865714.

Janus antimicrobial nanoparticles embedded in polymers

USPTO published patent application US20260091127A1 for Janus antimicrobial nanoparticles with distinct hydrophobic and polycationic surfaces embedded in crosslinked polymers. The invention aims to enhance traditional antibiotics and reduce necessary dosages against multi-drug resistant bacteria. Application No. 19344327 was filed September 29, 2025, and published April 2, 2026.

SKIN DEEP LASER MD Trademark Registration

USPTO renewed trademark registration TM86493579 for SKIN DEEP LASER MD covering cosmetic skin care services including laser skin rejuvenation, tattoo and hair removal, chemical peels, micro-needling, dermaplaning, and medical aesthetic procedures with dermal fillers and neuromodulators. The registration was originally filed December 31, 2014.

Berenson-Allen Center trademark registered, brain stimulation services

The USPTO registered trademark TM86525758 for the Berenson-Allen Center for Noninvasive Brain Stimulation covering medical services, education and training in noninvasive brain stimulation techniques, and conducting research and clinical trials. The trademark covers International Class 044 medical services including transcranial magnetic stimulation and transcranial direct current stimulation applications for diagnostic, therapeutic, and neurorehabilitation purposes. Registration was filed February 5, 2015 and granted April 1, 2026.

Allergy & Asthma Network trademark renewal

USPTO renewed Trademark Registration TM86461390 for Allergy & Asthma Network, effective April 1, 2026. The trademark covers medical information services, public health awareness programs, and educational services related to asthma and allergies. This is a routine 10-year trademark renewal under standard USPTO procedures.

Shelton Heart Center trademark registered for cardiac care services

The USPTO registered trademark TM86503569 for "Shelton Heart Center" covering cardiac hospital health care services. The trademark application was originally filed on January 14, 2015, and was officially registered on April 1, 2026. This registration grants the holder exclusive rights to use the mark in connection with the specified services.

Uroverse Trademark Registration - Medical Services and Pharmaceuticals

USPTO granted trademark registration TM79392893 to UROVERSE on April 1, 2026, covering medical services, digital rehabilitation apps, dietary supplements, pharmaceuticals, and medical software platforms. The trademark was filed on February 15, 2024. No compliance actions are required from industry participants.

Cosmetic Uses of Phaeodactylum Tricornutum Hydrolysate

USPTO published patent application US20260090979A1 by MICROPHYT covering cosmetic uses of a hydrolysate derived from an ethanolic extraction coproduct of the microalgae Phaeodactylum tricornutum. The invention targets skin exfoliation and reduction of skin microrelief for cosmetic and nutraceutical applications.

Mascara Composition with Sunflower Seed Wax

L'ORÉAL published patent application US20260090978A1 for mascara composition containing sunflower seed wax, tribehenin, and behenyl behenate. The invention provides improved aesthetics with total wax content of 5-35% by weight and combined wax blend of 5-20%. Application filed September 2024 with inventors David CHAN and Geoffrey WHITE.

Cosmetic Base Patent with Polymer Formula for Moisturizing Effect

Shiseido Company, Ltd. filed USPTO Patent Application US20260090976A1 for a cosmetic base composition containing a polymer formula designed to provide both use sensation and moisturizing effect. The polymer has a number-average molecular weight not exceeding 10,000 and an IOB value between 0.4 and 1.8. The application was published on April 2, 2026 with Filing Date August 31, 2023.

Cosmetic Compositions for Skin Firming Using Escin Extracts

USPTO published Mary Kay Inc.'s patent application for cosmetic compositions containing escin and botanical extracts for treating sagging, loose skin and improving facial contouring. The application includes methods comprising topical application of compositions with escin, Ascophyllum nodosum extract, caffeine, Coleus barbatus extract, and other plant-based ingredients. This is an informational publication with no regulatory compliance requirements.

Contact Lenses with Medicament Coating for Drug Release in Glaucoma Treatment

MEDIPRINT OPHTHALMICS INC. filed patent application US20260090984A1 for contact lenses incorporating medicament coatings for controlled drug release, specifically targeting glaucoma treatment through sustained delivery of drugs such as bimatoprost. The application covers the lens composition including N-vinylpyrrolidone, soaking solutions, and methods for loading and refreshing drug-eluting contact lenses. This patent application (No. 19411056, filed December 5, 2025) names six inventors including Praful Doshi and Brandon Huang.

Pediatric parenteral nutrition, oil-in-water emulsion, multi-chamber containers

USPTO published patent application US20260090983A1 for pediatric parenteral nutrition formulations comprising lipid emulsions in oil-in-water form. The application also covers multi-chamber containers for separating carbohydrate, amino acid, and lipid formulations until administration. Inventors include Jean-Luc Trouilly, Mary Hise Brown, Laurent Jeannin, Julien Hecq, and Julie Fahier.

Transdermal Delivery Formulations

USPTO published patent application US20260090981A1 for LifeActive, Inc., covering transdermal delivery formulations combining weak organic acids with fatty acid microemulsions for epicutaneous administration of therapeutic agents, drugs, and nutrients. The formulations are designed for use in high humidity conditions such as showers or saunas.

Water-in-oil cosmetic composition

USPTO published patent application US20260090977A1 for a water-in-oil cosmetic composition comprising specific silicone components (A) and (B) along with silicone powder (C), designed to improve stability, spreadability, and layered makeup durability. The application was filed September 7, 2023, with inventors Masaru Miyauchi, Masayuki Konishi, Yoshinori Inokuchi, and Ryuji Horiguchi.

Selectively Automated Robotic Surgical System

The USPTO published patent application US20260090850A1 by MAKO Surgical Corp. for a robotic surgical system allowing users to select between automated and manual operating modes for saw tool manipulation. The system includes a control system that associates target planes with anatomy and operates the manipulator according to the selected mode. The application was filed on 2025-12-08 under Application No. 19411441.

Headache Detection and Treatment System

USPTO published patent application US20260090763A1 for a headache detection and treatment system. The invention describes a flexible patch with electrodes for detecting and treating headaches through electrical nerve stimulation. Inventors include Constance Cardasis, William C. Altmann, Ann G. Yee, Pheng Dang, and Hoo-min D. Toong. Filing date: December 9, 2025.

Obstructive Sleep Apnea Episode Detection System

USPTO published patent application US20260090762A1 by inventor Hoo-Min D. Toong for an Obstructive Sleep Apnea Episode Detection System using audio frequency analysis. The system analyzes audio data during sleep to detect tongue position changes based on formant patterns, generating signals when obstructive sleep apnea episodes occur. Application No. 19413014 was filed December 9, 2025 and published April 2, 2026.

Instrument Articulation Dampening

USPTO published patent application US20260090852A1 by Auris Health, Inc. for instrument articulation dampening in surgical devices. The invention covers a robotic medical instrument with a base, shaft, articulation pull wires, robotic drive input, pulley, and pulley brake configured to apply friction for resistance to rotational movement. Inventors: James Hayes, Adrian Hairrell.

Surgical Robotic Microwave Waterjet System

USPTO published patent application US20260090847A1 for a surgical robotic system combining microwave ablation and high-pressure waterjet cutting technology, filed by Beijing Shijitan Hospital, Capital Medical University. The system includes a microwave blade with curved cutting edge, cooling support, and integrated high-pressure jet pipe controlled via a mechanical arm.

MAKO Surgical robotic arm deflection estimation using machine learning

MAKO Surgical Corp. published patent application US20260090848A1 on April 2, 2026, describing machine learning techniques for estimating deflection of surgical robotic arms. The invention uses tool pose and interaction force inputs to train models that predict arm deflection and characterize tool-anatomy interactions during surgical procedures.

Image Registration Method for Surgical Robot

Tinavi Medical Technologies Co., Ltd. filed USPTO Patent Application US20260090849A1 for an image registration method for surgical robots. The method captures 2D surgical images, acquires 3D images with preoperative planning data, and uses an iterative similarity-matching algorithm to project planning information onto the surgical view. The application was published April 2, 2026.

Medical Device Determines Cardiac Risk Using T-wave Repolarization Measurements

USPTO published patent application US20260091236A1 by inventors Hernandez and De Groot for a medical device and method that determines cardiac event risk using T-wave repolarization measurements. The device derives T-wave loops from up to two cardiac electrical signals and determines metrics of changes in repolarization measurements to assess cardiac risk.

Biological Status Classification via Health Informatics

The USPTO published patent application US20260092926A1 for a method of classifying biological status using health informatics. The method analyzes patient samples to quantify endogenous analytes and compares results to gender-matched healthy reference data to classify patients as healthy, pre-diseased, at risk, or diseased. Inventors include Paul John Innocenzi, Stephen Peter Fitzgerald, and Ivan Robert Mcconnell.

Training Device and Attribute Data Generation Device Using AI for Health Analytics

USPTO published patent application US20260093784A1 by NEC Corporation disclosing an AI-based training device and attribute data generation system for health analytics. The system uses machine learning encoders and decoders with latent variable clustering to generate health attribute data for disease risk assessment and activity decision support. No regulatory obligations or compliance requirements are created.

System and Method for Multi-Modal Dosing Device

USPTO published patent application US20260091177A1 filed by Kaival Labs, Inc. for a system and method for multi-modal dosing of a product. The invention provides a control base that couples to different cartridges containing products, where each cartridge has a unique identifier to confirm user authorization and prevent conflicting products. The application covers CPC classifications A61M 5/31546 and related medical device categories.

Expandable Sheath with Braided Polymer Layers

Edwards Lifesciences Corporation published patent application US20260090902A1 for an expandable sheath with multi-layer braided polymer construction, including an inner polymeric layer, braided filaments, and encapsulated elastic layer. The application was filed December 5, 2025, and published April 2, 2026.

Mechanical Automatic Injection Pen

USPTO published patent application US20260091176A1 for a mechanical automatic injection pen by inventor Guohui YE. The invention comprises a first assembly with pulling assembly, push rod, locking assembly, and elastic assemblies, and a second assembly with an actuating assembly for controlled injection operations. The filing date of the original application was September 16, 2022.

Catheter Management Device and Method for Continence Care

The USPTO published patent application US20260090933A1 by inventors Shawcross and Grey for a wedge-shaped positioning device designed to accommodate fecal management catheters. The device features a channel on its underside made from non-stick material to prevent backflow and leakage of waste contents onto patients or bedding. This invention addresses catheter blockage scenarios where leakage can occur.

Medication Tracking System

USPTO published patent application US20260091173A1 for a medication tracking system that monitors drug delivery via smart pumps and alerts clinicians to dosing anomalies. Inventors Jesse J. Guerra, Prabhu Chinnaiah, and Richard Stor Wu filed Application No. 19308777 on August 25, 2025.

Implantable Spacer with Pressure-Controlled Delivery Valves

USPTO published Patent Application US20260091174A1 for an implantable spacer designed to deliver medical fluids through pressure-controlled valves. The spacer features a channel system with multiple delivery valves on its outer surface that open reversibly based on fluid pressure within the implant. Inventors: Sebastian VOGT and Thomas KLUGE. Application No. 19343410.

Medtrum Drug Delivery System with Graphical User Interface

The USPTO published patent application US20260091175A1 by Medtrum Technologies Inc. covering a drug delivery system with graphical user interface for insulin infusion and blood glucose monitoring. The system includes a detection device, infusion device, and control device with GUI displaying insulin infusion status and blood glucose information. Filing date was September 13, 2022.

Resin Puncture Needle with Groove Structure

USPTO published patent application US20260091178A1 by DAIWA CAN COMPANY for a resin puncture needle with an integral groove structure. The needle includes a body portion with a fluid passage, a puncture portion, and a groove portion with protrusions that form a channel communicating with the passage. Inventors: Toshihiro ASANO and Makoto TAKAMI. Application No. 19413343 filed December 9, 2025.

Annual Return 2026: Care Provider Submission and Publication Requirements

Care Inspectorate Wales (CIW) has opened the 2026 annual return window for registered adult and children's care service providers in Wales. The deadline for submission is 23:59 on 26 May 2026 via CIW Online. This year introduces new requirements under the Health and Social Care (Wales) Act 2025, including mandatory provider website publication by 30 June 2026, and a combined data collection process with Social Care Wales.

Biomarkers for Alzheimer's Disease Diagnosis and Treatment

USPTO published patent application US20260091025A1 by Electrophoretics Limited covering biomarker panels for Alzheimer's disease diagnosis and treatment. The application claims panels including PP1 regulatory subunit 14A, CNPase, and phosphorylated tau proteins, along with methods for diagnosing and staging neurocognitive disorders using casein kinase 1 delta inhibitors.

Compositions and Methods for Enhancing Wnt Signaling for Treating Cancer

USPTO published patent application US20260091038A1 on April 2, 2026, disclosing compositions and methods for enhancing Wnt signaling pathway activities for treating cancer, particularly cancers with APC gene mutations. The application covers pharmaceutical compositions containing GSK-3 inhibitors, preferably LY2090314, encapsulated in nanoparticles. Inventors are George Eng, Omer Yilmaz, and Jonathan Braverman. Application number 19294146 was filed August 7, 2025.

BabA Antibodies for Preventing H. pylori Gastric Disease

USPTO published patent application US20260091099A1 by inventors Borén and Hammarström covering recombinant blood group antigen-binding adhesin (BabA) compositions that raise antibodies targeting conserved epitopes in the Leb antigen binding domain of BabA. The application discloses methods for preventing H. pylori-associated gastric diseases including gastric cancer, peptic ulcers, and gastritis without eradicating the infection.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091093A1 disclosing methods of treating plantar fibromatosis. The application (No. 19288249) was filed August 1, 2025, and names five inventors including James P. Tursi and Jeffrey David Lehrman. The invention relates to therapeutic methods using compositions classified under A61K 38/4886.

Tick Immunity Compositions and Methods

USPTO published patent application US20260091095A1 by inventors Erol Fikrig and Sukanya Narasimhan for compositions and methods generating tick immunity. The application (No. 19320550) was filed September 5, 2025, and published April 2, 2026. The invention covers pharmaceutical compositions for tick immunity under CPC classifications A61K 39/0003, A61P 33/14, and related subclasses.

Mycobacterium Vaccine Compositions for Immune System Modulation

The USPTO published patent application US20260091098A1 by inventor Bruce S. Gillis covering methods and compositions using killed or inactivated Mycobacterium or antigenic fragments for modulating immune system function. The application was filed September 12, 2025, under Application No. 19327636. This is a published patent application and does not grant any rights or impose obligations on third parties at this time.

Edwards EVOQUE Tricuspid Delivery System Labelling Recall

Health Canada issued a Type II voluntary recall for Edwards EVOQUE Tricuspid Delivery System (Model 9850TDS) affecting all lots. This labeling correction does not require product return but is intended to update device labeling to support proper use and optimal performance. Healthcare providers using this device should review updated labeling materials.

Dimension Creatinine CRE2 Medical Device Recall

Health Canada issued a Class Type II medical device recall for Siemens Healthineers Dimension® Creatinine (CRE2) diagnostic reagents due to potential imprecision in quality control and patient sample results. Affected lots GA6307 and BA7005 (catalog 10872079) may produce inaccurate creatinine measurements on the Dimension system. Healthcare facilities using these products should immediately quarantine affected inventory and contact Siemens for return or replacement options.

Implant Systems and Methods for Stabilizing Vertebral Bodies from a Posterior Approach

The USPTO published patent application US20260090896A1 filed by Foundation Surgical Group, Inc. on September 8, 2025. The application discloses an implant system comprising staples, a cage, and a coupling mechanism designed for stabilizing vertebral bodies from posterior and posterior-lateral approach trajectories. The system employs keyway mechanisms for staple-cage coupling and is configured for PLIF and TLIF spinal procedures.

Expandable Interbody Device Spinal Prosthesis

The USPTO published patent application US20260090897A1 for an expandable interbody device used as a spinal prosthesis during surgery. Filed December 10, 2025 by inventors Jordan Bauman, Ravi Enneti, and Jay Yadav, the device includes a drive block, top and bottom endplates, and dual drive arrangements with screws, slides, and linkages to provide spinal stability. The application was published April 2, 2026.

Expandable Bone Implant Patent for Orthopedic Surgery Restoration

USPTO published patent application US20260090895A1 by Lock-In VCF SA for an expandable bone implant for human orthopedic surgery. The implant features a biocompatible metal alloy hollow body that transitions from folded to deployed configuration via fluid injection, designed for restoring bone volume and geometry. Medical device manufacturers in the orthopedic space should review for competitive intelligence purposes.

Deployable Bistable Auxetic Expandable Interbody Spacer

USPTO published patent application US20260090894A1 disclosing a deployable bistable auxetic expandable interbody spacer for spinal applications. The invention by Troxell, Paul, and Johnson enables medical implants to transition between stable planar and 3D configurations. Application No. 18899689 was filed September 27, 2024, and published April 2, 2026.

Shoulder prosthesis anchoring device with baseplate and central pin

USPTO published patent application US20260090890A1 for a shoulder prosthesis anchoring device in reverse configuration. The application claims a baseplate with a central pin featuring an inner duct with helical cavity. Inventors are Andrea Rosa, Francesco Siccardi, and Massimiliano Bernardoni. Application No. 19114921 was filed September 28, 2023.

Patient-specific spinal implant design from image data

USPTO published patent application US20260090891A1 for patient-specific spinal implant design methodology. Invented by Michael J. Cordonnier, the method uses image data of the spine to measure geometric characteristics, applies mathematical rules, and generates 3D implant geometry for additive manufacturing. The application (No. 19321091) was filed September 5, 2025 and published April 2, 2026.

Tibial augment block patent

USPTO published patent application US20260090889A1 for a tibial augment block invented by Ting DENG, Qing LEI, Zhuo ZHANG, and Song CHEN. The patent covers an arc-shaped insert with a connecting plate for tibial osteotomy procedures, including a connecting hole at a specified angle and a connector mechanism.

Magnetic Knee Prosthesis System

USPTO published patent application US20260090892A1 filed by inventor James M. Jackson for a magnetic knee prosthesis system using repulsive magnetic forces between femoral and tibial components to potentially improve joint function. The application, filed December 9, 2025 under Application No. 19414239, covers A61F classifications related to orthopedic knee implants.

Reverse Shoulder Glenoid Baseplate System

The USPTO published patent application US20260090893A1 for a reverse shoulder system including a glenoid baseplate with a stem featuring a central channel within the sidewall. The longitudinal axis of the glenoid baseplate is angled relative to the stem axis and is not perpendicular to it. Inventors are Donald E. Running, Robert J. Ball, and Jason Slone. Filing date was December 5, 2025.

Belt for Applying Pressure to a Bodily Organ - Tricuspid Valve Regurgitation Treatment

The USPTO published patent application US20260090888A1 by Muffin Incorporated for a belt or band device designed to treat tricuspid valve regurgitation. The invention includes heat-set configurations to decrease the tricuspid annulus when deployed around the atrioventricular groove, along with tensioning sutures for cinching and force distribution structures. Application was filed December 8, 2025.

Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors

The USPTO published patent application US20260092045A1 for substituted benzofuran, benzopyrrole, benzothiophene compounds and structurally related compounds as complement system inhibitors. The application was filed on December 8, 2025, with 11 named inventors including Pravin L. Kotian, Yarlagadda S. Babu, and Weihe Zhang. The compounds may be formulated as pharmaceuticals for treating diseases characterized by aberrant complement system activity.

CFTR Modulator Patent, Pharmaceutical Compositions, Treatment Methods

The USPTO published patent application US20260092047A1 disclosing CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds of Formula (I), their pharmaceutical compositions, methods of treating cystic fibrosis, and processes for making the modulators. The application also covers solid state forms of Compound 1 and salts and solvates thereof. The application was filed on May 13, 2025, with Application No. 19206359.

Quinoline cGAS Antagonist Solid Forms and Salts

The USPTO published patent application US20260092048A1 for solid forms and salts of a quinoline cGAS antagonist compound, filed by inventors Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, and Zhijian Chen (Application No. 19316546, filed September 2, 2025). The application discloses the compound's cGAS antagonist properties, methods of preparation, pharmaceutical compositions, and use in medical therapy.

Dual Inhibitors for Alzheimer's Disease Treatment

USPTO published patent application US20260092039A1 for dual inhibitors (soluble epoxide hydrolase and glutaminyl cyclase inhibitors) useful for Alzheimer's disease treatment. Inventors from Spain and Germany filed Application No. 19161626 on March 4, 2024, with the application published April 2, 2026. The compounds also reduce pro-inflammatory cytokines, exhibit low cytotoxicity, and have good blood-brain barrier permeability.

Cyclopropane Carboxylic Acid Synthesis Methods

The USPTO published patent application US20260092040A1 for methods of preparing substituted cyclopropane carboxylic acid compounds. Inventors Nikolaos Papaioannou, Michael Jonathan Fray, Andreas Rennhack, and Sarah Jocelyn Fink filed the application on September 20, 2023 (Application No. 19113778). The application covers synthetic routes for these chemical compounds, which have potential uses in pharmaceutical development.

Process for Preparing Fluoro-imino-dihydropyrimidine Compounds

The USPTO published patent application US20260092041A1 for Adama Makhteshim Ltd., covering a process for preparing fluoro-imino-dihydropyrimidine compounds and derivatives. The application was filed on 2025-10-08 under Application No. 19352947. Inventors include Gal Suez, Samaa Alasibi, and Yaakov Mines.

Ipconazole preparation process patent

USPTO published patent application US20260092042A1 by inventors Mittal, Kini, Mukadam, and Shelkar disclosing a process for preparing Ipconazole, a triazole fungicide used in agriculture. The application, filed September 13, 2023, and published April 2, 2026, claims a cost-effective and environmentally friendly synthesis method suitable for large-scale industrial production.

Novel Benzoxazole Derivative Comprising 4-Amino-Butanamide and Anti-Inflammatory Use

USPTO published patent application US20260092043A1 by EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION disclosing novel benzoxazole derivatives comprising 4-amino-butanamide and their anti-inflammatory pharmaceutical applications. The application (No. 19115423) was filed March 14, 2023 and published April 2, 2026.

Pyrimidine Derivative for Inflammation Treatment

USPTO published patent application US20260092044A1 by ASKA Pharmaceutical Co., Ltd. for a pyrimidine derivative with mPGES-1 inhibitory activity for treating inflammation, pain, and rheumatism. The application was filed December 8, 2025, and names Makoto Okada, Youichi Nakano, Takashi Nose, Satoshi Maeda, and Tomoaki Watanabe as inventors.

Quinoline Butenamide Maleate Salts for EGFR Cancer Treatment

The USPTO published patent application US20260092046A1 covering maleate salt forms of a quinoline-based butenamide compound designed to target epidermal growth factor receptor (EGFR) family kinases for cancer treatment. Invented by Quinhong Lu and colleagues, the application discloses crystalline forms, preparation methods, and pharmaceutical compositions. The patent application was filed on May 5, 2025, and published on April 2, 2026.

Broad Institute Gene Editing Patent for SMA Treatment

The USPTO published patent application US20260091141A1 by Broad Institute, Inc. covering gene editing methods, systems, and compositions for treating spinal muscular atrophy (SMA). The application (No. 19288071) was filed on August 1, 2025, and made publicly available on April 2, 2026. Inventors include David R. Liu, Mandana Arbab, and Zaneta Matuszek. The application covers modified messenger RNAs and delivery methods for treating microbial infections or improving subject health.

Rod-Derived Cone Viability Factor Fusion Protein

USPTO published patent application US20260091133A1 disclosing a fusion protein comprising rod-derived cone viability factor-S (RdCVF-S), a hydrophilic peptide, and a signal peptide. The invention covers encoding nucleic acids, viral vectors, and pharmaceutical compositions for potential treatment of ocular conditions. Inventors: Tianci LUO, Daniel LIPUT, Fong Qi LIANG. Application No. 19339969 filed September 25, 2025.

Recombinant AAV Vectors for Treating Proteinopathies in CNS

The USPTO published patent application US20260091134A1 by Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors encoding Progranulin (PGRN) and/or Stathmin-2 (STMN2) for treating proteinopathies in the central nervous system. The application, filed November 26, 2025 (Application No. 19401460), includes codon-optimized coding sequences and viral particle compositions.

Epilepsy Treatment via Thalamus Bistable Opsin Gene Therapy

USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy using thalamus-administered bistable type II opsin gene therapy with light activation. The application (No. 19403102) was filed November 27, 2025, and published April 2, 2026. The invention targets drug-resistant epilepsy via optogenetic modulation of thalamic neural circuits.

ENHO gene therapy using Adropin for heart failure

The University of Pittsburgh filed a patent application (US20260091136A1) covering gene therapy methods using Adropin encoded by the ENHO gene for preventing and treating cardiometabolic diseases, specifically heart failure with preserved ejection fraction (HFpEF). The application was published on April 2, 2026.

Retron Gene Editing Patent for Human Cell Genome

USPTO published patent application US20260091137A1 for Retron directed gene editing technology applicable to human cell genome editing. The application, filed September 15, 2023, by inventors Brian Busser and colleagues, covers compounds, polypeptides, compositions, and nucleic acid molecules for genome editing. Key CPC classifications include gene editing enzymes and genetic constructs.

Variants of Coagulation Factor VIII and Uses Thereof

USPTO published patent application US20260091138A1 by Seattle Children's Hospital covering FVIII (coagulation factor VIII) protein variants with an N2118Q mutation for hemophilia A treatment. The application claims variants with reduced immunogenicity, higher gene expression, increased stability, and enhanced functional activity suitable for protein replacement therapy and gene therapy applications.

FOXG1 Gene Therapy Patent - Viral Vectors

USPTO published patent application US20260091140A1 for gene therapy constructs and viral vectors treating FOXG1 haploinsufficiency syndrome. Invented by Sarah Elizabeth Sinnett, the application (No. 19346144) includes FOXG1 encoding nucleic acids with miRNA regulatory elements to limit overexpression in vivo.

AAV Gene Therapy for Hypertrophic Cardiomyopathy

USPTO published patent application US20260091139A1 for AAV gene therapy compositions targeting reduced cardiac myosin binding protein C levels in subjects with hypertrophic cardiomyopathy. The application (filed September 22, 2023, Application No. 19113698) names six inventors including Peter Cameron Colosi and Eduard Ayuso. This is a publication notice with no immediate compliance obligations.

Wearable Thermal Sensors for Subdermal Fluid Monitoring

The USPTO published patent application US20260091172A1 by Rhaeos Inc. disclosing a wearable thermal sensor system for monitoring subdermal fluid levels. The system includes at least six temperature sensors, three thermal actuators, a flexible substrate, and a microprocessor configured to trigger alerts based on calculated alert conditions from temperature readings.

Electric Nasal Suction Device with Secondary Air Gap Chamber

The USPTO published patent application US20260091167A1 for an electric nasal suction device featuring a secondary air gap chamber positioned between a collection chamber and an air pump. The application was filed on January 16, 2025, by inventors Sophia Fornaro, John Fritz, Bailey Denton, and Chelsea Hirschhorn. The device falls under CPC classification A61M 1/67 and A61M 2210/0618, indicating medical suction apparatus technology.

Infusion pump syringes with reduced flexing, improved sealing

The USPTO published patent application US20260091168A1 for syringes designed for infusion pumps with reduced flexing and improved sealing. Invented by James Jacobson et al., the application (filed September 18, 2023) covers syringe barrel, plunger rod, and seal designs suited for infusion pumps with frequent start/stop operations at low flow rates. CPC classifications include A61M 5/1452 and related subclasses.

Dual-Plunger Syringe Assembly for Administering Multiple Fluids

The USPTO published patent application US20260091171A1 for a dual-plunger syringe assembly that enables administration of multiple fluids through a single device. Inventor Abraham C. Ng filed the application (No. 18902936) on October 1, 2024. The design embeds a second plunger within a first plunger, allowing sequential or simultaneous delivery of two distinct fluids.

Safety control system of a drug injection system

The USPTO published patent application US20260091170A1 for a safety control system of a drug injection system, filed by inventors Chin-Min YEH and Chih-Wei WANG. The system includes a contact end cap and confirming switch to activate a control unit for injection preparation, improving safety performance. Application No. 18899532 was filed on September 27, 2024.

Pump Device and Associated Method for Medication Delivery

The USPTO published patent application US20260091169A1 for a pump device with chamber, plunger, retainer, rods, and button mechanism designed for controlled medication delivery through an outlet. Assignee is Evanesce Medical, Inc. with four inventors. The application was filed on September 30, 2025.

Removable Inlet Manifold for Medical Waste Collection System

The USPTO published patent application US20260091166A1 on April 2, 2026, disclosing a removable inlet manifold for medical and surgical waste collection systems. The manifold features a tube that extends through an inlet port into a manifold cage and engages a complementary valve in the receiver to regulate fluid flow. Inventors include Andrew Mills, David Noskowicz, Brian Barkeley, Zachary Zott, and Stuart Mintz. Application No. 19412854 was filed December 9, 2025.

Apparatus for Extracorporeal Blood Treatment and Method for Determining Water Losses in Membrane Gas Exchanger

The USPTO published patent application US20260091165A1 by Dominique Pouchoulin for an apparatus used in extracorporeal blood treatment. The invention includes a method for determining water losses in a membrane gas exchanger by measuring sweep gas flow rate and water saturation content at the gas outlet. This technology applies to dialysis and similar blood treatment systems.

Hybrid Antibody-Peptide Molecule for Autoimmune Dermatitis

Université Toulouse III – Paul Sabatier has published patent application US20260091122A1 for a hybrid molecule combining an antibody Fc fragment with a peptide targeting autoreactive lymphocytes involved in autoimmune dermatitis. The invention covers the covalent bonding of the Fc portion to the targeting peptide and its therapeutic applications for treating autoimmune skin conditions.

AAV NDP Gene Therapy for NDP-Related Diseases Including Norrie Disease and Retinopathy

USPTO published patent application US20260091131A1 by University of Massachusetts inventors disclosing AAV constructs encoding wildtype or codon-optimized NDP gene sequences for treating Norrie disease, diabetic maculopathy, retinopathy, and other NDP-related retinal diseases. The application, filed October 10, 2023, covers methods of administration including intravitreal injection for retinal neovascularization and exudation conditions.

Nanocomposite for Targeted Degradation of Pathogenic Proteins

USPTO published patent application US20260091129A1 by inventors Zhang et al. disclosing a nanocomposite system for targeted degradation of pathogenic proteins using a maleimide-PEG-PLA nanocarrier with cationic lipids and protein-targeting binding peptides. The invention enables degradation of protein aggregates through autophagy pathways, addressing limitations of PROTAC and LYTAC technologies, with applications in anti-tumor treatments and Huntington's disease.

Chimeric Antigen Receptors Binding Nectin-4 for Cancer Treatment

The USPTO published patent application US20260091114A1 by Fred Hutchinson Cancer Center disclosing Chimeric Antigen Receptors (CARs) with binding domains that target Nectin-4, derived from murine antibody M22-321b41.1. The CARs are designed for expression in immune cells to treat Nectin-4-expressing cancers including bladder, breast, ovarian, esophageal, lung, colorectal, and pancreatic cancers. Application No. 19112145 was filed September 14, 2023.

PSMA-STEAP1 Dual Variable Domain Immunoglobulin DVD-Ig Molecules and Drug Conjugates

AbbVie Inc. filed US Patent Application US20260091121A2 for dual variable domain immunoglobulin (DVD-Ig) molecules binding human PSMA and STEAP1 antigens and their drug conjugates. The application (No. 18958236) was published on April 2, 2026 following filing on November 25, 2024. Competitors should monitor this IP position as it may cover cancer therapeutic constructs targeting these prostate cancer-associated antigens.

Click-to-Release Biotech Patent for Proteins and Peptides

The USPTO published patent application US20260091124A1 by inventor Michael Lukesch for a click-to-release technology involving modified peptides or proteins combined with bioorthogonally modified drugs. The application, filed September 20, 2023, and published April 2, 2026, covers bioorthogonal functional groups that enable targeted drug delivery systems for therapeutic applications.

NORIS EZGUIDE Dental Instruments Trademark Application

USPTO published trademark application TM79434671 for "NORIS EZGUIDE" covering Class 10 dental/medical instruments including burrs, drills, reamers, implants, surgical guides, and osteotomy tools. The mark was filed August 26, 2025, and published for opposition on April 1, 2026. Third parties may file opposition before the deadline if they claim likelihood of confusion with existing marks.

RAVN Trademark - Carbon Coatings for Medical Devices

USPTO received trademark application TM99385624 for "RAVN" covering carbon-based coatings for medical and surgical orthopedic implants and instruments. The application was filed September 10, 2025 under Intent-to-Use basis, including coatings for surgical instruments sold as integral components with amorphous diamond-like carbon (ADLC) surface coatings.

NAVISNARE Trademark - Vena Cava Filter Retrieval Device

USPTO received Trademark Application TM99440135 for NAVISNARE, a medical device trademark covering a vena cava filter retrieval device. The application was filed on October 13, 2025, under an Intent to Use basis. No compliance obligations or deadlines arise from this filing for third parties.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091092A1 on April 2, 2026, disclosing methods of treating plantar fibromatosis. The application (No. 19288073) was filed August 1, 2025, with inventors James P. Tursi, Luis A. Ortega, Qinfang Xiang, Saji Vijayan, Jeffrey David Lehrman, and David Hernandez. The patent covers therapeutic approaches using compounds classified under A61K 38/4886 and A61K 9/0019.

Halogenated Phenol Antimicrobial Composition

The USPTO published patent application US20260091002A1 filed by Industry Academic Cooperation Foundation of Yeungnam University for a halogenated phenol derivative composition with antimicrobial and antibiofilm activity against Staphylococcus aureus and pathogenic microorganisms. The application, filed June 10, 2025, covers the composition, methods of use, and treatment of biofilm-related infections.

4-Hexylresorcinol pharmaceutical composition for bone disease treatment

The USPTO published patent application US20260091001A1 filed by Kyungpook National University Industry-Academic Cooperation Foundation for a pharmaceutical composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for the prevention or treatment of bone diseases, including osteoporosis. The application claims formulations including ointments that demonstrated improved bone thickness, density, and strength in osteoporosis-induced animal models by promoting osteoblast differentiation and suppressing osteoclast proliferation.

Incretin Analog Dosing and Composition Methods for GLP-1 GIP GCG Tri-Agonists

The USPTO published patent application US20260091088A1 disclosing dosing regimens and compositions for long-acting incretin analogs comprising glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) tri-receptor agonists suitable for once-weekly administration. The application covers methods for treating metabolic conditions including obesity (A61P 3/04) and diabetes (A61P 3/10).

P55gamma as Therapeutic Target for Aortic Dissection

The USPTO published patent application US20260091091A1 claiming p55γ as a therapeutic target for aortic dissection (AD). The inventors from China demonstrated that p55γ overexpression inhibits AD formation and elastic fiber degradation in β-aminopropionitrile fumarate (BAPN)-induced mouse models. The patent covers using p55γ as a screening target for drugs to prevent and/or treat AD.

Incretin analog tri-receptor agonist compositions for weekly dosing

USPTO published patent application US20260091087A1 disclosing dosing regimens and compositions for long-acting incretin analog tri-receptor agonists targeting GIP, GLP-1, and glucagon receptors for once-weekly administration. The application (No. 19393199) was filed November 18, 2025, and names Tamer Coskun, Zvonko Milicevic, and Shweta Urva as inventors.

ML Algorithm Guides Ultrasound Probe for Abdominal Scans

USPTO published patent application US20260090786A1 for a machine learning algorithm that analyzes ultrasound images to guide operators in positioning probes for optimal abdominal scans. The system identifies anatomical structures, provides real-time positioning guidance, and tracks structural changes across multiple imaging sessions.

Robotic navigation system for spinal surgery alignment correction

USPTO published patent application US20260090842A1 by inventors Patrick Murray et al. covering a surgical navigation system that creates plans to correct deformed spinal alignments using image processing and robotic guidance. The system includes processors configured to generate correction plans and provide real-time navigation during spinal surgery procedures.

Fujifilm multi-energy radiation color imaging processor

USPTO published patent application US20260090776A1 by FUJIFILM Corporation for an information processing apparatus that acquires multi-energy radiation imaging data and generates color images based on energy information indices. The application (No. 19322696) was filed September 9, 2025 and published April 2, 2026. Inventors include Taiga Goto and Fuyuhiko Teramoto.

System and Method for Monitoring Respiratory Rate Measurements

USPTO published patent application US20260090772A1 by Masimo Corporation inventors Ammar Al-Ali, Bilal Muhsin, and Michael O'Reilly for a system and method using multiple physiological parameter inputs to determine multiparameter confidence in respiratory rate measurements from acoustic sensors combined with non-acoustic sensor inputs. The application covers patient monitoring systems that output confidence indications to assist clinicians in treatment decisions.

Hemorrhage identification from brain images with treatment guidance

USPTO published patent application US20260090841A1 by inventors Ahmed Kashkoush and Mark Bain for a system identifying brain hemorrhages from medical images and generating treatment guidance. The invention uses anatomical landmarks to normalize hemorrhage maps and compare them against dissimilarity heat maps to recommend treatment plans. The application (No. 19342833) was filed September 29, 2025 and published April 2, 2026.

Amplifier Interface for Multi-Electrode Catheter

USPTO published patent application US20260090755A1 for an amplifier interface system used in multi-electrode cardiac catheter procedures. The invention by Brian Pederson and Greg Olson describes a switching matrix that selectively couples catheter electrodes to amplifier channels, allowing flexible electrode selection despite a fixed number of amplifier channels. The system classifies under CPC categories A61B 5/304 and A61B 18/10.

Wearable ECG Systems with Automatic Vagus Nerve Stimulation

The USPTO published patent application US20260090757A1 by inventor David C. Shaw for wearable electrocardiogram (ECG) monitoring systems with automatic anti-arrhythmia capabilities. The application covers ECG systems that record from ears, fingers, or toes and include transcutaneous auricular vagus nerve stimulation (taVNS) to automatically detect and treat serious cardiac arrhythmias. Filing date was September 18, 2025.

Skin Condition Examination Using Electric Field Imaging

USPTO published patent application US20260090760A1 by inventor Hrand Mami MAMIGONIANS on April 2, 2026. The application discloses a method for examining visible skin conditions by combining camera-based image capture with electric field imaging to assess depth of skin penetration through correlation of surface area and volume measurements.

Wearable Device for Measuring Skeletal Muscle Hardness

USPTO published patent application US20260090761A1 by J.Schmalz GmbH for a wearable measuring device designed to monitor skeletal muscle hardness using multiple force sensors with varying spring constants. The device includes a holding apparatus for attachment to body parts and can detect tensioning forces from different muscle sections.

Cognitive-Impairment Diagnostics For Schizophrenia

USPTO published patent application US20260090758A1 by Bristol-Myers Squibb Company for a method of diagnosing cognitive impairment in schizophrenia patients using electrical brain activity measurements. The invention processes neural activity data from electrodes attached to a patient's head along with stimulation data to determine modulation depth for cognitive assessment.

Medical Image Processing Apparatus for Brain Vessel Imaging and Surgical Device Placement

Canon Medical Systems Corporation filed patent application US20260090754A1 for a medical image processing apparatus that generates vessel diameter images and distance images to identify candidate placement positions for surgical devices in the brain. The system combines brain blood vessel imaging with functional and nerve activity data to assist in surgical planning. Application No. 19324359 was filed on 2025-09-10.

Wearable Cardiovascular Hemodynamic Monitoring Device

USPTO published patent application US20260090753A1 for a wearable non-invasive hemodynamic monitoring device with flexible body, electrode wings, and sensors for continuous cardiovascular parameter tracking. The invention by Deepanjan Datta and Sai Kamalesh Rayaprolu covers bioimpedance, ECG/EKG, and accelerometer sensors in a modular design with wireless transmission capabilities for ambulatory healthcare use.

Atrial Fibrillation Trigger Detection Using Electrode Signal Correlation

USPTO published Biosense Webster (Israel) Ltd.'s patent application (US20260090756A1) for a method of detecting atrial fibrillation triggers using composite correlation scores based on signals from multiple electrodes. The invention relates to electro-anatomical mapping systems that identify suspected AF trigger locations in the heart by analyzing electrode signal correlations. Application No. 18903377 was filed October 1, 2024.

ASXL1 Disruption in T Cells for Immunotherapy Enhancement

The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.

Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 by Matthew Wood et al. covering cell-penetrating peptides with dual hydrophobic domains for treating genetic disorders, specifically Duchenne muscular dystrophy. The application (filed October 21, 2025) discloses peptide compositions and conjugates with therapeutic molecules. This is a publication of a pending application and does not yet grant enforceable patent rights.

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Amino acid-modified lipids enable RNA delivery via lipid nanoparticles

USPTO published patent application US20260091126A1 for amino acid-modified lipids designed for RNA delivery via lipid nanoparticles (LNPs). The application, filed September 19, 2023, by inventors Kun Cheng and Pratikkumar Vinodchandra Patel, covers siRNA, mRNA, miRNA, shRNA, and oligonucleotide delivery formulations. The technology targets oncogene silencing applications.

Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen

USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Biallelic Knockout of CTLA4

The USPTO published patent application US20260091113A1 by inventor Rafi Emmanuel covering compositions and methods for biallelic knockout of CTLA4 using RNA guide sequences. The application includes 4,891 sequence variants (SEQ ID NOs: 1-4891) with potential therapeutic applications. Filed September 18, 2023; published April 2, 2026.

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

The USPTO published patent application US20260092038A1 disclosing novel cannabinoid receptor 1 (CB1) antagonists/inverse agonists for treating metabolic disorders including diabetes, dyslipidemia, cardiovascular disorders, obesity, and cancer. Invented by Marshall Morningstar, the application covers compound compositions and therapeutic uses. Filing date was September 26, 2025.

Crystalline Benzamide Salt Forms for T-Type Calcium Channel Diseases

USPTO published patent application US20260092037A1 disclosing crystalline salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for treating T-type calcium channel diseases including epilepsy, essential tremor, and major depressive disorder. The application (No. 19311876) was filed August 27, 2025, naming inventors David T. Jonaitis and Lisa McCracken.

Indole Derivatives as Serotonergic Agents for CNS Disorders

USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.

7-Azaindole Analogs and Serotonin Agonists for Neurological Disorders

The USPTO published patent application US20260092034A1 for 7-azaindole analogs as serotonin receptor agonists for treating neurological disorders. Assigned to Kuleon LLC with inventor David Gilles, the application covers both hallucinogenic and non-hallucinogenic compounds. The patent application was filed December 8, 2025, under application number 19412382.

Crystalline T-type calcium channel salt patent

The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.

Passive Alignment of Commissures in Prosthetic Heart Valve Implantation

St. Jude Medical, Cardiology Division, Inc. published a patent application for a delivery device enabling passive alignment of commissures during prosthetic heart valve implantation. The device features an inner shaft, outer shaft, distal sheath, and a biasing spine that directs bending in a pre-determined direction to facilitate proper valve positioning. The application (US20260090886A1) was published April 2, 2026, with a filing date of December 9, 2025.

Heart valve prosthesis with leaflet clipping mechanism

The USPTO published patent application US20260090885A1 for a heart valve prosthesis featuring a leaflet clipping mechanism. Inventors Ji Zhang, Brandon G. Walsh, Cheng Yong Yang, Jinhua Zhu, and Dennis McMahon disclosed a device combining a valve anchor with U-shaped members, an expandable valve frame, and a link mechanism that collectively engage prosthetic or native valve leaflets. The application claims priority to filing date December 1, 2025.

Epicardial Device and Methods for Right Heart Support During LVAD

The USPTO published patent application US20260090887A1 for an epicardial implant system designed to prevent right heart failure following left ventricular assist device (LVAD) implantation. Inventor John M. MacMahon's device provides dual-mechanism support through separate adjustable elements for ventricular wall constraint and tricuspid valve annular geometry optimization. Preclinical validation demonstrated six-minute implantation with independent component efficacy.

Prosthetic Heart Valve with Paravalvular Leak Mitigation Features

USPTO published patent application US20260090880A1 by St. Jude Medical for a prosthetic heart valve with paravalvular leak mitigation features. The application claims novel cuff configurations and finger elements positioned radially outward from stent cells, along with tapered struts for improved fatigue resistance. The filing date is December 8, 2025.

Prosthetic Frame Covers Patent Application

The USPTO published patent application US20260090881A1 for prosthetic frame covers for valvular prosthetics. The application, filed by 6 inventors including Radhika Vaid and Jessica Louise Blair, describes systems and methods for synthesizing covers via depositing, submersion, and/or printing techniques. The covers can be applied directly onto valvular frames or transferred from temporary substrates.

US patent US20260090878A1 for intraocular lens delivery tools

US patent US20260090878A1 for intraocular lens delivery tools

Drug Eluting Heart Valve Prosthesis Patent

The USPTO published patent application US20260090879A1 by inventor Theodoros Kofidis for a heart valve prosthesis with embedded drug eluting mechanisms. The application was filed on September 13, 2023, and covers prosthesis designs incorporating various therapeutic drug compounds for localized delivery during implantation.

Prosthetic Valve for Native Atrioventricular Valve Implantation

The USPTO published patent application US20260090882A1 for an implantable prosthetic heart valve designed for native atrioventricular valve replacement. The application, filed by 8 inventors, describes a radially collapsible and expandable valve with serpentine arm anchors. This publication represents a published patent application; no regulatory compliance obligations are created.

Sinus-Engaging Valve Fixation Member

Medtronic Ventor Technologies Ltd. filed USPTO patent application US20260090883A1 for a sinus-engaging valve fixation member used in prosthetic valve delivery systems. The application, published April 2, 2026, describes methods for delivering and deploying valve prostheses using engagement arms that flare outwardly during deployment. The invention relates to A61F classifications covering cardiac and vascular prosthetics.

Mechanical Guides for Controlling Leaflet Folding Behavior During Crimping

The USPTO published patent application US20260090884A1 for mechanical guides controlling leaflet folding behavior during crimping of transcatheter valve prostheses. The invention by inventors Grant Menon, Yogesh Darekar, and George Hallak includes a leaflet folding accessory with guide fingers configured to hold leaflets in predetermined configurations during compression. The technology applies to transcatheter aortic and other heart valve replacements.

Cellular Oxidative and Mitochondrial Stress Protection Compositions

NUCHIDO LIMITED filed USPTO Patent Application US20260090969A1 for compositions protecting cells from oxidative and mitochondrial stress. The application discloses a combination of bioactive compounds including NMN, NR, resveratrol, curcumin, and other cellular stress protectors for pharmaceutical and cosmetic applications. Published April 2, 2026.

Composition for Promoting the Skin Microbiome

USPTO published patent application US20260090967A1 for a skin microbiome promoting composition. The application claims a combination of carbon sources (glucose, fructose, saccharose, maltose, maltodextrin, pyruvic acid, pyruvate, lactic acid and lactate) and nitrogen sources (alanine, glycine, arginine and urea), and/or caprylic/capric triglycerides. Inventors include Jennifer Huepeden, Mirja Laschet, Karen Tom Dieck, Heike Foelster, and Sabine Sellckau.

Sodium DNA Lipid Nanoparticle Drug Delivery Patent

USPTO published patent application US20260090968A1 for a lipid nanoparticle composition containing sodium DNA as an active ingredient, with applications in pharmaceutical drug delivery systems. The composition includes sodium dilauramidoglutamide lysine as an amphiphilic surfactant, distearoylphosphatidylcholine as an auxiliary surfactant, cholesterol as a stabilizer, and auxiliary stabilizers including PEG-120 stearate, polyglyceryl-4 caprate, and PEG-PCL copolymer. Filing date is October 10, 2023.

Aneurysm Treatment System and Method

The USPTO published patent application US20260090808A1 for an aneurysm treatment system invented by Aamir Badruddin et al. The system includes a wire with an occlusion element featuring a cover and inner anchoring member designed to treat aneurysms by covering the neck portion and contacting the interior aneurysm surface. Application No. 19410959 was filed December 5, 2025.

Urolithin oral care compositions patent application

USPTO published patent application US20260090966A1 for urolithin-based oral care compositions including toothpaste, mouthwash, gels, and chewing gum with therapeutic or cosmetic effects. The application covers compositions comprising urolithins, methods of treatment, and formulations with additional active ingredients such as fluoride. Inventors include Christopher L. Rinsch, Davide D'Amico, Anurag Singh, and Charlotte Tissot.

LifeActive Transdermal Delivery Formulations Patent Application

USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.

Aspirin Oral Mucosal Formulations

USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.

Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions

Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.

Delayed Release IBD Treatment Composition

Aihol Corporation filed patent application US20260090996A1 for a delayed-release oral pharmaceutical composition containing mesalamine and hyaluronan layers for treating inflammatory bowel disease. The USPTO published the application on April 2, 2026, with Application No. 19399068 and a filing date of November 24, 2025. This patent covers novel multi-layer coating technology for targeted drug delivery to the colon.

Polymer Nanoparticle Compositions for NF1 Treatment

The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.

Cat Food Composition for Treating or Preventing Urolithiasis

The USPTO published patent application US20260090570A1 for a cat food composition designed to treat or prevent urolithiasis (urinary stones) in cats. The wet and dry compositions include omega-3 fatty acids from flaxseed and fish oil, along with pH-modifying ingredients such as calcium sulfate, methionine, sodium acid pyrophosphate, taurine, and potassium sulfate. The application was filed on October 1, 2024, under application number 18903721.

Orodispersible Estetrol Dosage Unit Patent

USPTO published patent application US20260090995A1 by ESTETRA SRL covering an orodispersible solid pharmaceutical dosage unit containing estetrol particles (0.1-25 wt.%) for sublingual, buccal, or sublabial administration. The dosage unit weighs 30-1,000 mg, contains at least 100 μg of estetrol component, and is manufactured via wet granulation of particles sized 2-50 μm. Application No. 19340502 was filed September 25, 2025.

Cat Food Composition for Treating Urolithiasis and Reducing Hairballs

The USPTO published patent application US20260090571A1 for a cat food composition targeting urolithiasis (urinary stones) and hairball reduction. Inventors Nolan Z. Frantz, Angela M. Gajda, and Todd Harper developed wet and dry formulations incorporating omega-3 sources (flaxseed, fish oil), acidifiers (calcium sulfate, SAPP), methionine, taurine, and dietary fiber to achieve urine pH between 6.15-6.85 and reduce RSS struvite to ≤1.8 and RSS oxalate to ≤6.0.

Fisher Clinical Services DEA Importer Registration Application

DEA published notice that Fisher Clinical Services, Inc. has applied to be registered as an importer of Schedule I controlled substance 3,4-Methylenedioxymethamphetamine (MDMA, drug code 7405) for use in clinical trials. The application was filed March 11, 2026, at the company's Pennsylvania facility. Comments and hearing requests are due May 1, 2026.

Royal Emerald Pharmaceuticals Bulk Manufacturer Registration Application

The DEA published notice that Royal Emerald Pharmaceuticals applied to be registered as a bulk manufacturer of Schedule I controlled substances including Marihuana Extract (7350), Marihuana (7360), and Tetrahydrocannabinols (7370). The company, located in Desert Hot Springs, California, plans to provide cannabis botanical raw material and API to DEA-registered researchers and manufacturers. Comments and objections on the application are due June 1, 2026.

Indivior Manufacturing LLC - Controlled Substances Importer Registration Application

The DEA published notice that Indivior Manufacturing LLC applied on February 26, 2026, to be registered as an importer of Thebaine (drug code 9333, Schedule II controlled substance). The company plans to import limited quantities for research, clinical trials, analytical purposes, and manufacturing process development of dosage forms. The public comment period closes on May 1, 2026.

Controlled Substance Importer Registration Application - MDMA

The DEA published notice that Fisher Clinical Services, Inc. applied on March 11, 2026 to be registered as an importer of 3,4-Methylenedioxy-methamphetamine (MDMA, Schedule I, drug code 7405) for clinical trials only. The company is located in Allentown, Pennsylvania. Registered bulk manufacturers and applicants may submit comments or objections, or request a hearing, by May 1, 2026.

Controlled Substance Importer Registration Application - Sterling Wisconsin LLC

The Drug Enforcement Administration published notice that Sterling Wisconsin, LLC applied for registration as a Schedule I controlled substance importer (drug code 7431 - 5-Methoxy-N,N-dimethyltryptamine). The application was filed January 27, 2026. Interested parties may submit comments or hearing requests by May 1, 2026.

Controlled Substances Importer Application - Research Triangle Institute

DEA published notice that Research Triangle Institute (Durham, NC) applied to be registered as an importer of controlled substances for 30 Schedule I drug classes including synthetic cathinones, benzodiazepine analogs, and other psychoactive substances. The application was filed March 3, 2026. Interested parties may submit comments or request hearings on the application through May 1, 2026.

HHS-Certified Laboratories for Urine and Oral Fluid Drug Testing

SAMHSA published a notice updating the current list of HHS-certified laboratories and instrumented initial testing facilities authorized to conduct urine and oral fluid drug testing for federal agencies. The document (91 FR 16718) maintains the registry of entities meeting minimum standards established under HHS guidelines. No new certification standards or requirements are being imposed.

Eye Tracking Machine Learning System for Physiological Assessment

RightEye LLC filed USPTO patent application US20260090750A1 for a system using eye tracking and machine learning to automatically assess physiological states. The invention captures eye movement data, processes it through an ML model trained to identify patterns associated with physiological characteristics, and outputs both the physiological state and recommended interventions. Application No. 19343212 was published April 2, 2026.

AnalYTE SENSORS AND METHODS OF USE THEREOF

The USPTO published Abbott Diabetes Care Inc.'s patent application (US20260090745A1) for analyte sensors capable of detecting biological analytes using multiple enzyme systems. Inventors Zenghe Liu and Benjamin J. Feldman developed the disclosed technology for medical diagnostic applications.

Devices and Methods for Body Fluid Sampling and Analysis

The USPTO published patent application US20260090746A1 for meters and methods for sampling, transporting, and analyzing body fluid samples. The invention includes a meter housing with imaging system, a cartridge with sampling arrangements, and skin-penetration members for fluid collection. Application filed May 8, 2025, by inventors Raul Escutia et al.

Anti-CCR8 antibodies and uses thereof - Vaccinex cancer treatment patents

Vaccinex, Inc. filed patent application US20260091108A1 covering anti-CCR8 antibodies and methods of treating cancer using those antibodies. The application, published April 2, 2026 with filing date November 19, 2025, names 11 inventors including Pamela M. Holland. CPC classifications indicate therapeutic antibody applications in oncology.

Method for Treating Alzheimer's Disease

The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease using sequential administration of anti-amyloid beta monoclonal antibodies in increasing doses to reduce ARIA risk. The application, filed June 16, 2025, names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors. This publication provides public notice of a pending patent application but creates no compliance obligations for third parties.

Self-assembling peptide gel for tissue lift, repair

The USPTO published patent application US20260091159A1 by Norchi et al. disclosing compositions containing self-assembling peptides that form stable in situ gels for tissue lift, repair, and bulking applications. The formulations are designed for use during endoscopic, laparoscopic, or open surgical procedures and provide hemostatic properties with adhesion prevention for periods of days to one month.

Metastatic cancer treatment using abscopal effect with radiotherapy

The USPTO published patent application US20260091085A1 assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising type 1 interferon combined with low-dose radiotherapy to induce systemic anticancer effects (abscopal effect) in metastatic cancer sites. The application claims a method where administering type 1 interferon with low-dose radiation to the primary tumor site produces anticancer effects at non-radiated metastatic sites.

Micronized Antibodies in Polymeric Particles for Drug Delivery

USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.

Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies

USPTO published patent application US20260090529A1 disclosing transgenic non-human animals that produce modified heavy chain-only antibodies (HCAbs). The invention involves substituting the native amino acid residue at the first position of framework region FR4 with a different residue to disrupt a surface-exposed hydrophobic patch, potentially improving antibody characteristics. Named inventors include Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, and Mike Osborn.

Amylin Receptor Agonist and GLP-1 Receptor Agonist Combination Therapy

USPTO published patent application US20260091086A1 for a combination therapy comprising amylin receptor agonists and GLP-1 receptor agonists. The application, filed on May 19, 2025, covers polypeptide combinations for therapeutic uses including weight management (A61P 3/04). Invented by Sarah WILL, the application represents a potential new approach to metabolic disorder treatment.

Universal T Cell CMV Vaccine for Influenza

USPTO published patent application US20260091102A1 for a universal T cell-based, CMV-vectored vaccine for influenza, filed by Oregon Health & Science University. The invention covers methods of generating immune responses and MHC-restricted T cells for treatment or prevention of pathogenic infections including influenza.

Underpressure Milk Expression Device with Infrasound Source

USPTO published patent application US20260091164A1 for a milk expression device utilizing underpressure and infrasound technology. The device includes a nipple-enclosing wall defining a chamber connectable to an underpressure generator, along with an infrasound source featuring a moveable member. Inventors include YanYk Parulian, Julian Bourquin, Okke Ouweltjes, and Anna Louise Wijnoltz. Application No. 19113061 was filed September 14, 2023.

Biological sample collection device

The USPTO published patent application US20260090793A1 for a medical apparatus designed to collect biological samples. The device comprises an elongate tubular body with an opening, a filter assembly with a mountable membrane for microscope slide analysis, and a base member for releasable engagement. Inventors include Anjali Saqi and Keith Yeager.

Capsule Inhaler for PDE4 Inhibitor for Respiratory Treatment

USPTO published patent application US20260090986A1 for a capsule inhaler for administering a PDE4 inhibitor for respiratory treatment, filed by CHIESI FARMACEUTICI S.P.A. The application claims a dry powder inhalation device with a pharmaceutical composition comprising micronized particles of a PDE4 inhibitor and a carrier. This is an informational publication of a pending patent application with no regulatory implications.

Double loop lasso catheter with single puller wire for bi-directional actuation

USPTO published patent application US20260090835A1 for a double loop lasso catheter with single puller wire enabling bi-directional deflection. The invention features a pre-bent puller wire with U-shape bend anchored at a deflectable section reinforced by washers with aligned holes for straight tensile force application. The proximal support member is flattened and serrated for improved bonding.

Surgical Stapling Device Tissue Compression Method with Visual Feedback

USPTO published patent application US20260090735A1 for a method of compressing tissue during surgical procedures with simultaneous visualization of tissue location within the device jaws. The invention enables surgeons to determine and display compressed tissue position through communication with a surgical hub. No regulatory compliance requirements apply.

Oral Irrigator Pump Body and Device

The USPTO published patent application US20260090867A1 for an oral irrigator pump body invention by inventor Lei Yu. The application covers a bracket-mounted power device and pump body structure with a transmission mechanism driving a piston assembly. The patent was filed on September 30, 2024, with application number 18902875.

Shaftless Micromotor for Optical Elements in Medical Catheters

The USPTO published patent application US20260090704A1 for a shaftless, brushless micromotor designed to rotate optical or sensing elements at the distal end of medical catheters. The invention uses the waveguide itself as the axle, eliminating blind spots and reducing motor size. Inventors include Ginger Schmidt, Brett E. Bouma, Milen Shishkov, and Néstor Uribe-Patarroyo. The application was filed September 19, 2023.

Cancer Treatment Patent - Two-Part Treatment Regime

The USPTO published patent application US20260091097A1 for a two-part cancer treatment regime involving antigen-specific T cell therapy followed by inflammation-inducing treatment. The application, filed on April 18, 2025, covers methods of treating cancer using sequential administration of treatments to generate tumor-specific immune responses. Inventors include Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, and others.

Cardiac Xenograft Rejection Measurement Methods

The USPTO published patent application US20260091096A1 disclosing methods for measuring cardiac xenograft immune rejection progress. The application covers transgenic pig preparations with reduced glycan antigens (Sda/SDa-like and α-Gal) and recipient immunological response modifications targeting CD46, CD59, CD9, PROCR, and ANXA2. Inventors are Guerard W. Byrne and Christopher G.A. McGregor, with priority date September 15, 2025.

Urate Oxidase-Albumin Conjugate Patent Application

USPTO published patent application US20260091090A1 for a urate oxidase-albumin conjugate invented by seven researchers. The conjugate uses three or more albumins conjugated through a linker to a urate oxidase variant, improving half-life and reducing immunogenicity. The invention addresses prevention and treatment of diseases caused by uric acid, such as gout and hyperuricemia.

Lipid Nanoparticle mRNA Vaccines

USPTO published patent application US20260090989A1 by CureVac SE for lipid nanoparticle mRNA vaccine compositions. The application covers cationic lipids according to formulas (I)-(III), PEG lipids per formula (IV), and mRNA encoding antigens for influenza and rabies vaccination. The filing (Application No. 19409837) lists 14 inventors including Patrick Baumhof, Mariola Fotin-Mleczek, and Michael J. Hope.

Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods

The USPTO published patent application US20260090997A1 by Sorscher et al. disclosing lipid nanoparticle compositions comprising nucleic acids encoding therapeutic genes for treating cancer. The application was filed September 20, 2023, and published April 2, 2026. Inventors include researchers from Emory University and Georgia Institute of Technology working on targeted gene therapy delivery systems.

Pyocyanin Demethylases Engineered for Bacteria

The USPTO published patent application US20260091089A1 for engineered pyocyanin demethylases with amino acid replacements at positions A53, 173, A87, T91, M99, A129, and K141 of PodA. The application covers compositions, methods, and systems for interfering with bacterial viability through pyocyanin demethylase activity, including synergistic combinations with antibiotics. Application 19312182 was filed August 27, 2025.

NADC34-like PRRSV-2 Vaccine Plasmid and Mutant Strain rBJ-VVL

Yangzhou University filed a patent application (US20260091100A1) with the USPTO for an rBJ-VVL plasmid and mutant NADC34-like PRRSV-2 strain with tropism for Marc-145 cells. The modified strain incorporates precise mutations at amino acid positions 91/97/98 of GP2a, enabling viral propagation and plaque formation in Marc-145 cells. This represents the first disclosed NADC34-like PRRSV-2-specific vaccine candidate derived from a Marc-145-adapted modified strain.

Culture and Kit-of-Part of Bacterial Strains

USPTO published patent application US20260090557A1 for bacterial cheese culture strains and kits for manufacturing pasta-filata cheese. The application covers galactose-positive Streptococcus thermophilus strains and methods for producing stretched curd cheese using defined culture combinations. Filing date was December 10, 2025.

Implantable Climacturia Treatment System

USPTO published patent application US20260090871A1 for an implantable system combining an inflatable penile implant with an inflatable urethral cuff for treating climacturia and erectile dysfunction. The system includes a pump operatively coupled to both components to enable synchronized inflation. Invented by Khaled Said Shouman, application filed September 26, 2025.

Double-Branching Ascending Aortic Stent-Graft System

Endospan Ltd. published patent application US20260090874A1 for a double-branching ascending aortic stent-graft system featuring an internal support channel within a main fluid flow guide. The system allows transition between collapsed and expanded states with an elongate member passing through proximal and distal openings. The invention aims to improve treatment of aortic conditions through enhanced deployment flexibility.

Soft Tissue Implant Systems, Instruments and Related Methods

USPTO published patent application US20260090877A1 by Paragon 28, Inc. for soft tissue implant systems comprising flexible anchor tubes with internal cavities and sutures configured to allow controlled translation between tubes when tensioned. The application (No. 19413835) was filed December 9, 2025.

Tissue Graft Fixation Methods and Devices

The USPTO published patent application US20260090876A1 for methods and devices used in tissue graft fixation, covering adjustable fixation loops and suture systems. The application, filed December 9, 2025, names 13 inventors and claims priority to Application No. 19413793.

Reinforced biological construct for tendon repair

The USPTO published patent application US20260090875A1 for a reinforced graft construct designed for tendon or ligament repair. The invention involves inserting reinforcement material such as suture, tape, weave, or mesh lengthwise through the graft, with ends whipstitched for fixation. The reinforcement may be bioabsorbable. Inventor: John KONICEK. Application filed December 8, 2025.

Embolic Protection Device

Shanghai Kegang Medical Technology Co., Ltd filed patent application US20260090873A1 for an embolic protection device comprising a metal wire or ribbon with elliptical or flat cross-section, pre-formed into a spiral structure wound around its short axis. The device is designed for deployment within blood vessels to intercept emboli, featuring enhanced shape recovery and reduced blood flow interference. Inventors include Zhichao Zhang, Wenzhe Wang, Hengyue Qian, Zhilong Zhou, Changsheng Ma, and Jianzeng Dong.

Pelvic Stabilization Implant Patent Application

USPTO published patent application US20260090872A1 for a pelvic stabilization implant on April 2, 2026. The application covers threaded implants for pelvic stabilization with an elongate body design, methods of delivery and manufacture. Filed August 5, 2025.

Intraocular Lens Selection via Ray Tracing

USPTO published patent application US20260090710A1 on April 2, 2026, disclosing a system and method for selecting intraocular lenses using ray tracing through pseudophakic eye models. The invention enables surgeons to pre-operatively compare multiple lens options and select the preferred lens based on simulated optical performance metrics. Inventors include George Hunter Pettit, Mark Andrew Zielke, John Alfred Campin, Martin Gruendig, and Daniil Nekrassov.

Men's urinary clamp with magnetic force, sliding mechanism

USPTO published patent application US20260090870A1 by inventor Han Yong Chun for a men's urinary incontinence clamp device utilizing magnetic force and a sliding mechanism. The application was filed on October 1, 2025, and published on April 2, 2026. The invention aims to improve wearing comfort by gradually applying force to the penis through a sliding clamp mechanism.

Life attitude testing system, evaluates vertical/horizontal/gaslighting states

USPTO published patent application US20260090748A1 by inventor Song Lee for a Life Attitude Test Method and System. The invention provides a computer-implemented testing method that evaluates users across four psychological states: vertical life, horizontal life, gaslighting state, and enlighting state. The system uses a test server to present questions and calculate total scores for each evaluation factor.

Robotic Surgical Systems Using Neural Network Calibration

USPTO published patent application US20260090851A1 from MAKO Surgical Corp. disclosing robotic surgical systems employing artificial neural networks for multi-robot calibration. Invented by Ali Talasaz, the invention addresses error compensation in master-slave cooperative robot systems by training ANN models to correct relative and absolute positioning errors. The system improves absolute accuracy and relative tracking precision after model-based geometric calibration.

Novel Heterocyclic Compounds for Pharmaceutical Use

Hoffmann-La Roche Inc. published patent application US20260092076A1 for novel heterocyclic compounds with pharmaceutical use. The application covers compounds having general formula I with defined R1, R2, R3, A and W substituents, related compositions, and methods of using the compounds. Filing date was October 7, 2025, under Application No. 19351608.

KRAS Inhibitor Heterocyclic Compounds for Cancer Treatment

USPTO published patent application US20260092075A1 for KRAS inhibitor heterocyclic compounds designed for cancer treatment. The application covers novel chemical compounds of specified formula, their pharmaceutical salts, and methods of using these compounds for treating cancer patients. Filing date was September 30, 2025.

VMAT2 Inhibitor Heterocyclic Compound and Preparation Method

The USPTO published patent application US20260091029A1 for a class of VMAT2 inhibitor heterocyclic compounds. The application, filed December 9, 2025 under Application No. 19414124, covers compounds represented by formula (I), their stereoisomers, and pharmaceutically acceptable salts. The inventors (Jingwei Tian, Rui Zhang, and seven others) also disclose preparation methods and applications for treating diseases related to VMAT2 and Sigma-1 receptors.

Composition Comprising Biosurfactant and Salicylic Acid

USPTO published L'OREAL's patent application for a skincare composition combining glycolipid biosurfactants with salicylic acid derivatives, cationic polymers, and clay for treating acne-prone skin. The application, filed September 30, 2024, covers formulations with water and glycerin solvents for topical use.

Hydrophobic Cellulose Powder for Cosmetic Applications

USPTO published patent application US20260090962A1 for surface-treated hydrophobic cellulose powder. The invention uses modified dextrin and/or modified amino acids to render cellulose powders hydrophobic, improving dispersibility, feel, and stability. The powders are intended for cosmetic applications including foundations, skin care, and hair care products.

Antiperspirant Cream Patent Application by Lume Deodorant LLC

The USPTO published patent application US20260090961A1 by Lume Deodorant, LLC for an antiperspirant cream composition containing water, an antiperspirant material, alpha-hydroxycarboxylic acid, an oil agent, and a structuring agent, with optional caffeine or xanthine derivatives. The application was filed on September 27, 2024, and names inventors Shannon Klingman, Stephanie Richmond, Rebecca Reynandez, and Nikita Bhatnagar. This is an informational publication of a patent application; no regulatory compliance obligations are created.

Vital Pulp Therapy Using Bioactive Composites

USPTO published patent application US20260090960A1 by Imam Abdulrahman Bin Faisal University for a method of vital pulp therapy using a bioactive capping material. The invention comprises a mixture of glass ionomer cement (GIC) and potassium nitrate (KNO3) in 1-10 wt.% concentration with a solvent. The application was filed September 30, 2024.

Process for Making Aqueous Therapeutic Particles with Nanosized Water Clustering

USPTO published patent application US20260090957A1 for a process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering between 1-300 nanometers. The invention, assigned to a multi-inventor team, claims improved bioavailability for therapeutic compositions including CBD, PNC-27 peptides, pharmaceuticals, and nutraceuticals through a computer-controlled continuous manufacturing process.

Depilatory Emulsion Containing Paclitaxel and Preparation Method

USPTO published patent application US20260090965A1 for a depilatory emulsion containing paclitaxel by inventor Ming Xia. The invention comprises 10-20% oil, 8-12% humectant, 4-6% emulsifiers, 8-12% paclitaxel solution, and auxiliary ingredients, designed to target hair follicles while preventing dermal absorption. A stepwise cooling and gradual emulsification method ensures stable emulsion formation.

Xanthommatin Color Additive for Food Beverage and Drug Compositions

USPTO published patent application US20260090963A1 by inventor Leila Deravi for xanthommatin as an edible color additive for food, beverage, and drug compositions at 0.01-0.5% wt concentration. The application covers substrates including foods, beverages, drinks, medications, and drug forms.

Maternal Health Strategic Action Plan Launch

The Shapiro Administration released Pennsylvania's first Maternal Health Strategic Action Plan, 'Healthy Moms, Vibrant Futures,' a multi-agency initiative aimed at reducing maternal health disparities and improving health outcomes for mothers and children. The plan contains strategic goals, data, ongoing work, and recommendations developed in coordination with the Department of Human Services, the Governor's Commission on Women, and maternal health advocates. Since January 2023, the administration has invested over $12.3 million in maternal and child health initiatives, with an additional $7.5 million proposed in the 2026-27 budget.

Governor Stein Proclaims April Child Abuse Prevention Month

NCDHHS and Positive Childhood Alliance NC recognize April 2026 as Child Abuse Prevention Month following Governor Josh Stein's proclamation. The campaign theme 'Positive Childhoods Start With Us' emphasizes community responsibility to support families. According to the CDC, at least one in seven children in the US experienced abuse or neglect in the past year.

Center for Scientific Review Notice of Closed Meetings

The National Institutes of Health (NIH) Center for Scientific Review published a notice announcing five closed meetings scheduled for April 28-29, 2026. The meetings involve review panels evaluating grant applications in neurological disorders, musculoskeletal sciences, HIV/AIDS research, and neuroimmune/neuroinflammation studies. Meetings will be held virtually and are closed under exemptions for confidential trade secrets and personal privacy protections.

Center for Scientific Review Notice of Closed Meetings

The NIH Center for Scientific Review published a notice announcing five closed meetings scheduled for April 27-28, 2026. The meetings will review and evaluate grant applications for various study sections covering neuroscience, genetics, biochemistry, and health promotion. Meetings are closed under Federal Advisory Committee Act provisions to protect confidential grant information and personal data.

National Eye Institute Meeting Cancellation

The National Eye Institute (NEI) has cancelled a meeting of the Board of Scientific Counselors scheduled for April 6, 2026, from 2:00 to 3:00 p.m. The meeting, which was to be held at NEI headquarters in Bethesda, MD, was previously noticed in the Federal Register on March 26, 2026 (91 FR 14703). A new Federal Register notice will be published once a rescheduled date is determined.

Priority Review Voucher Issuance; KRESLADI Rare Pediatric Disease Product

FDA announced the issuance of a priority review voucher to Rocket Pharmaceuticals, Inc. for KRESLADI (marnetegragene autotemcel), approved March 26, 2026, for treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). The voucher was awarded under section 529 of the FD&C Act's Rare Pediatric Disease Priority Review Voucher Program. This notice fulfills FDA's statutory requirement to publish voucher awards.

Siren Biotechnology ITM Trademark for Gene Therapy

USPTO published Siren Biotechnology's intent-to-use trademark application for the stylized mark 'SIREN BIOTECHNOLOGY' covering pharmaceutical preparations for gene therapy for cancer treatment and related research and development services. The application (TM99737013) was filed on March 31, 2026, with an Intent-to-Use filing basis indicating the applicant has not yet used the mark in commerce but intends to do so.

THEVO Labs Trademark Application - Dietary Supplements

The USPTO published trademark application TM99737126 for THEVO LABS covering dietary supplements and online retail store services. The application was filed on March 31, 2026, and published on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

Advisory Board on Radiation and Worker Health Charter Renewal

The CDC published a notice announcing the charter renewal of the Advisory Board on Radiation and Worker Health (ABRWH) in the Federal Register. The board operates under the Department of Health and Human Services to advise on radiation protection and worker health matters. This renewal continues the board's advisory functions without substantive changes to its mission or authority.

NCVHS Public Meeting Announced for April 2026

The CDC published a Federal Register notice announcing a public meeting of the National Committee on Vital and Health Statistics (NCVHS). The meeting is scheduled for April 16, 2026, from 5:30 p.m. to 7:30 p.m. EDT. Public attendance is permitted; no new regulatory requirements or policy changes are established.

ONCOASSIST Trademark Published for Opposition

The USPTO published trademark application TM99736989 for ONCOASSIST on April 1, 2026, opening a 30-day opposition period. The application, filed March 31, 2026, covers Class 44 medical services including cancer research promotion, medical education advertising, and health information services.

Crysvita Severe Hypercalcemia Risk Communication

Swissmedic, in coordination with Kyowa Kirin, issued a Direct Healthcare Professional Communication (DHPC) warning of severe hypercalcemia risk associated with Crysvita (Burosumab). Cases of elevated serum calcium, including life-threatening hypercalcemia, have been reported, particularly in patients with tertiary hyperparathyroidism. The communication establishes contraindications for patients with moderate to severe hypercalcemia (>3.0 mmol/L) and provides updated monitoring protocols.

VIGOR&VEDA Ayurvedic herbal wellness trademark application

USPTO received trademark application TM99292393 for VIGOR&VEDA (Intent to Use basis) filed by an undisclosed applicant on July 19, 2025. The application covers online retail services for nutritional supplements and apparel, dietary supplements, and athletic apparel. The statutory use deadline is March 31, 2026.

WIZZWELL Incontinence Products Trademark Application

USPTO published trademark application TM99275999 for WIZZWELL, covering incontinence products for men including absorbent pads, disposable bags, and supportive boxer briefs. The application, filed July 10, 2025, claims intent to use the mark by March 31, 2026. No opposition period or compliance deadlines are associated with this application.

Final Dose Trademark - Probiotic Supplements and Vitamins

The USPTO received trademark application TM99208312 for 'FINAL DOSE' filed on May 29, 2025. The application covers International Class 005 products including probiotic supplements, vitamins, dietary supplements, and nutritional products under an intent-to-use basis.

GEMSLEAF Trademark Application - Intent to Use

The USPTO received a trademark application for GEMSLEAF filed on July 21, 2025, under Serial No. TM99293830. The application is based on Intent to Use provisions and covers natural herbal supplements, dietary supplements, sleep aid preparations, and various beverages including water, carbonated drinks, and coconut water. The applicant has until March 31, 2026, to either use the mark in commerce or file for extension.

Strict Scrutiny Applied to Colorado Conversion Therapy Ban

The U.S. Supreme Court ruled 8-1 in Chiles v. Salazar (No. 24-539) that Colorado's law banning conversion therapy by licensed counselors constitutes content- and viewpoint-based regulation of speech subject to strict scrutiny under the First Amendment. The Court rejected Colorado's argument that the law merely regulates professional conduct, finding instead that it directly targets speech and prescribes permissible viewpoints. The case was remanded to the Tenth Circuit for application of strict scrutiny.

Mayor Bowser Kicks Off Earth Month and 10th Annual Spring Cleanup

Mayor Muriel Bowser and District of Columbia leaders announced the 10th Annual Spring Cleanup scheduled for April 25, 2026, and highlighted spring cleaning services resuming across the city. The Department of Public Works announced expanded food waste collection options, a new recycling partnership with the DC Housing Authority, and will now administer the Mayor's Office of the Clean City and Adopt a Block program.

Board of Acupuncture, Chiropractor and Naturopathic Physicians Newsletter

DC Health published the Winter/Spring 2026 newsletter for the Board of Acupuncture, Chiropractor and Naturopathic Physicians. The newsletter provides informational updates on DC Health services including the DC Health and Wellness Center, professional licensure resources, and contact information for licensed practitioners in the District of Columbia.

Health First Vitamin E Recall - Undeclared Active Ingredient

Health Canada issued a Type III recall for Health First Vitamin E capsules (NPN 80089888, lots 14042 and HL2252701) distributed by Health First Network in Hamilton, Ontario. The recall affects retailers and targets products containing an undeclared active ingredient. Consumers are advised to consult healthcare providers before discontinuing use. The recall was initiated on April 1, 2026.

Flamingo Funnel Medical Device Recall - Sterility Loss Risk

Health Canada issued a Type II recall for Flamingo Funnel™ medical devices (lots 8264501, 8264601, 8264701, model SQ-20012-01) manufactured by Nascent Surgical D/B/A SurgiSmoke Solutions. The recall was initiated due to a packaging defect where a non-gamma-compatible drape degraded under heat, causing pinholes and potential loss of sterility. Healthcare providers must immediately stop using affected lots and dispose per national and local regulations.

DermaHealer UVB Light Therapy Lamps Recalled for Lacking Canadian Medical Device Licence

Health Canada issued a Type II recall for DermaHealer UVB Light Therapy Lamps (Handheld and Compact models) distributed in Canada without required Canadian Medical Device Licence. The products were sold to customers across Canada by manufacturer DermaHealer USA/UAB FavouritePlus of Tualatin, Oregon. No specific lot or model numbers are available; customers must contact the manufacturer for identification.

B. Braun Hemodialysis Blood Tubing Set Recall - Air Bubble Risk

Health Canada issued a Type II recall for B. Braun Hemodialysis Blood Tubing Sets (models B3-4630M4705 and B3-3632M3705) due to potential accumulation of small air bubbles in the arterial line caused by adherence of blood gases to tubing under negative pressure. All lots are affected. Healthcare providers should immediately identify and remove affected products from use and contact the manufacturer for return or replacement instructions.

Kiwi Vacuum Assisted Delivery System Recall - Breakage Hazard

Health Canada issued a Type II recall for Clinical Innovations' Kiwi® Vacuum Assisted Delivery System (model VAC-6000MT) due to a breakage hazard at the Traction Force Indicator joint during use. The device may break when traction is applied at approximately a 45-degree angle, posing a risk during obstetric procedures. Manufacturers will contact affected customers with instructions for product return.

Jamieson Laboratories Natural Health Products Recall - Defective Tamper-Evident Seals

Health Canada has issued a Type III recall for three Jamieson Laboratories natural health products due to potentially defective tamper-evident seals. Affected products include Joint pain relief capsules (Lot 70794), Magnesium bisglycinate Capsules (12 lots), and Maca capsules (3 lots). Wholesalers, retailers, and consumers are advised to verify product lots and consult healthcare providers regarding use.

Waterbody-Specific Fish Consumption Advisories Updated

The New York State Department of Health updated fish consumption advisories for waterbodies statewide. For the first time in 50 years, the Department relaxed advisories for the Lower Hudson River due to declining PCB levels, allowing the general population to eat up to four meals per month of certain fish including striped bass. More restrictive advice was issued for other waters including Lake Ontario, Lake Erie, and several rivers due to PFOS contamination.